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Historically, drugs have mainly been small chemical compounds synthesized from 
natural sources.  But with the advent of recombinant DNA technology, protein-based 
drugs, or biologics, have become a significant fraction of the pharmaceutical industry.  
Biologics are larger and more complex than standard small molecule drugs which gives 
them greater specificity and potency, but also makes them difficult to characterize and 
formulate.  The primary issue is that at the high protein concentrations used in many 
formulations, biologics are prone to aggregation which can cause unsafe and painful drug 
administration.  Common methods for characterization and analysis of protein stability 
and/or aggregation often require different physical or chemical conditions than those 
present in formulation and provide little or no predictive power, necessitating long 
incubation times for shelf life determination.  To combat this problem and further our 
understanding of protein aggregation I have developed isothermal calorimetry for use in 
measuring the rates of unfolding and aggregation for high concentrations of protein at 
temperatures well below those used in traditional DSC experiments.  I have compared 
and confirmed isothermal calorimetry results for a candidate HIV vaccine called VRC07-
523LS in formulation to data obtained using other widely used experimental techniques 
and found that predictions of long-term stability rank order for a set of buffers correlate 
precisely with the results obtained using SEC.  The ability to measure unfolding and 
aggregation rates at high protein concentrations and with relatively mild denaturing 
conditions results in more accurate predictions of the shelf life of biologics and allows the 
direct investigation of protein stability at the high concentrations used in formulations, 
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Chapter 1.  Introduction 
 
Biologics 
For much of human history, medicines were limited to natural sources, mainly 
from various plants and fungi.  In 1869 the first synthetic drug, chloral hydrate, was 
introduced as a sleeping aid (4).  This marked the beginning of the age of “small 
molecule” drugs, often synthesized from the aforementioned natural sources, leading to 
the development of a fledgling pharmaceutical industry led by companies like Bayer in 
Germany (4).  These companies largely grew out of the textile and synthetic dye 
industry and soon developed synthetic barbiturates, analgesics, and antipyretics, 
highlighted by the discovery of aspirin, which is still widely used and administered today 
(4).  The serendipitous discovery of penicillin through observation of a contaminated 
Petri dish also provides an illustrative example of the drug development process during 
this time period.  A major advance occurred in the 1970’s with the development of 
recombinant DNA technology, which gave pharmaceutical companies more control over 
drug development through genetic engineering.  Rather than identifying and mass 
producing naturally occurring drug molecules, now they could engineer microorganisms 
to produce lucrative and useful drugs.  Genentech, a biotechnology company formed by 
University of California-San Francisco researchers in 1976, provided perhaps the best 
example of this new utility with the production of insulin using Escherichia coli in 1978 
(5).      
 Today, the definition of biologics has grown with the ability to produce a wider 
array of molecules.  Biologics are generally defined as any large molecule produced 
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from living cells used in the treatment or prevention of human disease (6).  Rather than 
chemical synthesis, they are produced by genetically engineering animal cells, bacteria, 
or yeast to make the desired product.  This engineering often adapts or exploits 
naturally occurring processes in the chosen cells, and the resulting products can be up 
to 1000 times larger than traditional small molecule drugs (6).  Biologics now include a 
wide array of molecules, from monoclonal antibodies, to recombinant hormones, to 
targeted gene therapies, but the term is also often used to generally refer to any protein-
based drug molecule (7).   
 With the expiration of patents on traditional chemical drugs, as well as the ability 
to specifically design biologics for particular targets, biologics are becoming one of the 
main sources of revenue for biotechnology and drug companies.  Small molecules will 
likely always compose a significant fraction of available drugs, as they are less time 
consuming, easier, and cheaper to manufacture than biologics, as well as being orally 
bioavailable for ease of administration (8).  But the advantages of biologics in regards to 
specificity and potency ensure that biologics will also maintain a significant market 
share. They have rapidly become, and are expected to continue to be, one of the 
largest segments of the pharmaceutical industry.  Biologics are projected to make up 
29% of the global pharmaceutical industry and 50 of the top 100 products by 2022 (9).  
More in-development biologics reaching the market as they gain approval will also 
contribute to this rapid increase in market share.   
The greater size of biologics in comparison to small molecules also translates to 
significantly more complex molecular structures (7).  The intricate secondary, tertiary, 
and even quaternary structures of biologics, plus post-translational modifications like 
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glycosylation, leads to much greater specificity but also poses a number of drawbacks.  
This complicated structure means that biologics are extremely sensitive to minute 
changes in manufacturing protocols which can significantly affect their medicinal and 
chemical properties (7).  Their multi-step production methods are often subject to small 
amounts of variation that can affect the properties of the drug, and are also frequently 
around 100-fold more expensive than chemical production methods for small molecules 
(7).  Further, characterizing their structural and physiochemical properties fully is often 
impossible, especially due to the fact that they can change with different manufacturing 
processes (7).  Additional issues are caused by the almost universal immunogenicity of 
biologics.  Drug companies seek to blunt the immune response in a variety of ways, 
frequently by using proteins that are partially or completely human homologs, but this is 
rarely a complete solution (7).  It is also imperative that reducing immunogenicity begins 
at the molecular design level of development by minimizing antigenic epitopes and 
developing molecules with favorable physical and chemical properties (7).  These 
immune responses may decrease the efficacy of the drug or lead to unwanted side 
effects, and can vary from low-level more generalized responses with very little 
consequences to the patient, to highly specific IgG responses that can potentially be life 
threatening (7).  These immune responses are also notoriously difficult to predict 
through non-clinical studies using biochemical assays, and the complexity of the human 
immune system often necessitates immunogenicity analysis through human trials (7).   
While oral administration is the gold standard for drug delivery, biologics are 
particularly difficult to take orally for a number of reasons.  Chief among them is that 
biologics are rapidly degraded in the GI tract by acid and proteolytic enzymes.  
4 
 
Combined with their poor permeability, this leads to poor bioavailability when 
administered orally (10).  In order to get around this problem, biologics are generally 
administered via intravenous (IV), subcutaneous (SC), or intramuscular (IM) injection.  
While IM injection is useful for between 2 and 5 mL injection volumes, it also is much 
more painful and has a high risk of complications due to the depth of the injection site 
below the skin (11).  Generally speaking, biologics are formulated to be delivered 
through either IV or SC injections.  IV administration is useful in that it can involve much 
higher volumes than other delivery methods and leads to rapid responses to the drug in 
the patient (11).  The issue with IV injections is that they require trained medical 
personnel to administer, and are time consuming due to their often large volumes and 
the necessary observation of the patient after treatment for negative side effects (11).  
This occupies both valuable space in the treatment center, as well as the time of 
specialized personnel.  SC administration is therefore the delivery method of choice for 
biologics in the absence of effective oral delivery.  The primary advantages of SC 
injections are that they can be administered by the patient, are not particularly painful, 
and multiple injection sites can be used in the case of multiple dosing (11).  This ease of 
administration leads to a higher rate of treatment compliance by patients as well as 
increasing their quality of life (11).  The downside to SC injections is that they require 
volumes less than 1 or 2 mL, which then requires very high drug concentrations in the 
formulation in order to achieve proper dosage, on the order of 100 mg/mL or greater 
(11).   
The high protein concentrations necessary for many biologic formulations can 
change the behavior of the proteins in solution and lead to a number of problems during 
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formulation development.  The most common of these problems are increases in the 
viscosity of the solution, decreases in the stability of the protein, and increases in its 
aggregation (12).  These issues can pose serious problems during drug development, 
transport, and storage, as well as eventual patient administration (12).   
High viscosity makes using filtration methods to achieve high concentration 
formulations difficult by contributing to loss of sample in the filtering apparatus, as well 
as a higher back pressure on the filter itself (13).  Injections of high viscosity solutions 
are also difficult and painful for patients to administer (13).  This increase in viscosity 
with higher concentrations of protein is caused by weak intermolecular interactions 
between protein molecules (14).  At higher protein concentrations there is a higher 
probability of individual protein molecules interacting than in dilute solutions, and this 
leads to the individually weak interactions between molecules having a larger overall 
effect on solution viscosity (14).   
Although the viscosity of a formulation must be kept in mind during formulation 
development, it is almost exclusively dealt with at the earliest stage of drug molecule 
selection by choosing a molecule that exhibits low viscosity before different formulations 
are extensively tested.  Once a specific drug molecule is chosen, it is often of greater 
concern and utility to monitor its stability and aggregation in a given formulation.  Protein 
aggregation and its effect on stability will be discussed in depth in Chapter 2 of this 
work.  In short, protein aggregation is a concentration dependent phenomenon, and, 
therefore, increases at higher protein concentrations.  Aggregation shifts the equilibrium 
towards the aggregating species, thereby affecting the Gibbs free energy (ΔG), which 
describes the equilibrium of the system.  ΔG increases with increasing concentration if 
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the protein aggregates in the native state, or decreases with increasing protein 
concentration if aggregation occurs in the denatured state.   
 Formulation development mainly involves identifying the formulation conditions in 
which the drug is most stable and easy to administer to patients.  While ease of patient 
administration, with minimal pain at the site of administration, is a concern during 
development, the primary indicator of formulation performance is the long term stability 
of the drug molecule.  Long term stability can be measured using a variety of methods, 
which will be discussed in more detail in the next section of this chapter.  These 
methods generally measure the fraction of protein in different oligomeric states.  As the 
active conformation of most drugs is native monomers, long term stability is usually 
quantitatively measured by the disappearance of monomer over time under different 
storage conditions. 
 A variety of factors are evaluated when choosing a formulation in order to insure 
relatively painless administration and drug stability, such as the pH and ionic strength of 
the buffer.  But the primary tool used to improve the stability of a drug during formulation 
development once a general pH range is chosen for the formulation is the addition of 
excipients.  Excipients are substances other than the drug or active ingredient that are 
added to the formulation.  They can serve a variety of purposes, like adding bulk to a 
small amount of drug, enhancing drug absorption by the body, or protecting the protein 
from certain types of stress (15).  Osmolytes, naturally ubiquitous small organic 
compounds that affect protein stability, are one of the largest classes of excipients (16).  
These compounds are classified as protecting or denaturing osmolytes based on 
whether they drive the equilibrium towards the native or unfolded state, respectively 
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(16).  For formulation development, protecting osmolytes are most useful, as they help 
to maintain the drug in its active, folded conformation.  They can be divided into three 
categories: (1) polyols, (2) some amino acids and (3) methylamines, each of which is 
thought to have evolved in response to different environmental stressors (17).  Polyols, 
like glycerol, sucrose, and trehalose, are particularly adept at protecting against large 
temperature swings and moisture losses (17).  Glycine, arginine, and some other amino 
acids are thought to have evolved to protect against extracellular environments with 
high salt concentrations (17).  Methylamines, on the other hand, which include 
compounds like trimethylamine N-oxide (TMAO), can protect cells from the unwanted 
negative effects of urea-rich environments (17).  But while these various classes of 
osmolytes may have evolved for different purposes in nature, they are all useful to 
varying degrees in protein formulations, particularly L-arginine and various polyols like 
sucrose and sorbitol.   
 When evaluating different formulations for a drug, as mentioned previously, the 
ideal formulation is one that minimizes protein aggregation and maintains the maximum 
fraction of protein in the active conformation in order to achieve maximum drug efficacy.  
A formulation that achieves these goals will also have maximal long-term stability, or 
shelf life.  These terms refer to how long the fraction of protein in the active 
conformation remains above acceptable levels, which is of utmost importance when 
bringing a drug to market, as it will have to be transported and stored for months or 
even years before patient administration.  This naturally leads to predicting and 
measuring the long term stability of drugs in different formulations as one of the most 
important aspects of formulation development.  Numerous techniques can be used in 
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this respect, which will be discussed in the next section.  Ones used to determine, 
rather than predict, the shelf life, typically measure the fraction of protein in different 
oligomeric states after different incubation times at various storage temperatures.   
 
Techniques used to analyze biologics 
 Size exclusion chromatography (SEC) is one of the most widespread and useful 
techniques in the pharmaceutical industry for assessing the long-term aggregation of 
protein therapeutics.  The technique itself is actually rather old, as size based 
separation of proteins was first theorized in 1944 and experimentally observed in 1955 
(18).  With the advent of protein-based therapeutics, it has seen a resurgence in interest 
and utility among pharmaceutical companies quantifying the aggregation of protein-
based drugs.   
 SEC is performed by running buffer containing the protein of interest over a 
column packed with a porous matrix using a liquid chromatography system.  This 
matrix, often referred to as the stationary phase, was originally composed of starch, but 
in the present day is composed of other materials (18).  The packing material should 
ideally be totally non-reactive with proteins and be very mechanically stable (18).  One 
of the most popular packing materials is cross-linked dextrans sold under the 
tradename Sephadex and originally developed by Pharmacia, but polyacrylamide based 
gels can also be used (18).  When buffer is run through the stationary phase, particles 
are separated by size based on the amount of time they spend inside the porous 
spheres making up the packed column bed.  Smaller particles are more likely to spend 
more time inside the spheres, while larger particles travel through the length of the 
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column with minimal occupancy inside the spheres, leading particles to elute from the 
column in size order from large to small as determined by their Stokes radius (18).  
Since the size of protein aggregates is directly proportional to the number of aggregated 
molecules, separating protein molecules by size is a simple and straightforward way of 
determining the degree of aggregation in a given sample.  Changing the particle or pore 
size for the stationary phase can be used to optimize the column for specific molecular 
sizes.   
 The primary way that SEC is utilized in the formulation development pipeline is 
assessing the shelf life of drugs in different formulations.  Samples are incubated at 
different storage temperatures for weeks at a time, and aliquots are taken out at 
numerous time points for aggregation assessment.  In this manner, a time course of the 
amount of protein aggregation in a sample can easily be constructed for different 
formulations.   
The draw backs to using SEC for aggregation assessment are mainly due to 
experimental constraints.  The protein concentration for an SEC experiment needs to be 
rather low, much lower than the ~100 mg/mL protein concentrations in most 
formulations (19).  The buffer used in the SEC run is also often not the same as the 
formulation buffer in order to minimize interactions between the stationary phase and 
the protein, which may be enhanced by certain excipients and can lead to results that 
do not reflect the true aggregation profile of the sample (19).  This means that the 
aggregation of the protein in question is analyzed in a different chemical and physical 
environment than it is stored in, which may lead to inaccurate results or conclusions if 
aggregation is affected by this change in environment (19).  If the molecules in question 
10 
 
are large enough, then they may even avoid entering the stationary phase particles 
altogether, and elute in the void volume of the column, thereby being indistinguishable 
from other particles in the void volume.   
SEC is the preferred method for measuring protein aggregation during 
formulation development, but results can sometimes be misleading due to non-specific 
interactions between the column matrix and the drug of interest, thereby necessitating 
orthogonal methods to confirm the results.  Analytical Ultracentrifugation (AUC) is 
responsible for much of our knowledge of macromolecules and their biophysical 
properties in solution gathered over much of the twentieth century (19).  Starting around 
the 1970’s, SEC began to replace AUC as the technique of choice for most researchers 
to assay protein aggregation and other structural parameters due to its ease of use (19).  
But with the realization that orthogonal techniques are often necessary to assess 
aggregation of biologics in solution, as well as a number of engineering and 
computational advances which have drastically improved the quality and quantity of 
information that can be obtained, AUC has seen a resurgence in use for analysis of 
biologics (19). 
  To conduct a standard sedimentation velocity AUC experiment, a sample is 
loaded in a sector shaped centerpiece.  Depending on the instrument and experimental 
set up, a reference solution may or may not be necessary.  The rotor is brought up to an 
appropriate speed and the concentration profile of the sample as a function of the radius 
at different times is collected and describes the migration pattern of all macromolecular 
species in the sample.  These curves can then be fit to obtain sedimentation and 
diffusion coefficients for the sample, as well as to determine how many molecular 
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species are present in the sample (19).  While performing the experiment itself is 
simple, the reason that AUC is likely better suited to a supporting role rather than 
replacing SEC altogether is due to the high cost of AUC instrumentation and the 
complexity of the data analysis.  But while AUC may not overtake SEC in utility during 
the formulation development process, it can provide key insights and confirmation when 
odd or unexpected results are encountered using SEC or other more widely used 
techniques. 
 Light scattering measurements, particularly dynamic light scattering, are another 
very common way of assessing the aggregate content of a protein sample.  Static (SLS) 
and dynamic (DLS) light scattering both have the same general set-up: a laser is 
focused on a clear cell containing dilute sample.  While most of the light will pass 
through the sample, some portion will be scattered by the sample particles in solution, 
and the intensity of the scattered light is detected at one or more angles (usually 15°-
180°) from the incident laser light.  DLS differs from SLS in that the scattered light 
intensity (most commonly at a 90° angle) is monitored over millisecond timescales to 
monitor the diffusive properties of the particles in solution (20).  There are numerous 
strategies to analyze the scattered light intensity in order to derive quantitative values 
describing the particles in question.  Generally speaking, SLS experiments are used to 
determine sample parameters like molecular weight and particle size (20).  DLS 
provides information on the hydrodynamic radius or radius of gyration, as well as the 
diffusion coefficient of the particles (20).  Through various analyses, other quantities like 
the second virial coefficient can also be determined, which indicates whether solute-
solvent interactions are attractive, repulsive, or neither (20).  Together, especially in 
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conjunction with other techniques like SEC, light scattering is a useful tool to quickly 
determine the degree of aggregation present in a protein sample.  MALLS (Multi-Angle 
Laser Light Scattering) is the primary type of light scattering used in conjunction with 
SEC, although it can also be used on its own.  MALLS measures the time-averaged 
intensity of scattered light with detection at multiple different angles to report on the 
molar mass and size of particles in solution (21).  It is often used online with SEC to 
collect qualitative information on the size-separated particles. 
While light scattering, primarily DLS and MALLS, is a useful tool to use in 
conjunction with other methods like SEC, it has similar drawbacks.  It requires much 
lower protein concentrations than those used in formulation, and also provides little 
predictive power.  The interpretation of the various parameters obtained from a light 
scattering experiment like the second virial coefficient can also not be straightforward 
for certain situations and data analysis can be very complicated (21).  Perhaps most 
importantly, light scattering is extremely sensitive to sample contamination such as dust 
particles, requiring filtration of the sample before measurements can be obtained, which 
can remove the aggregates of interest to the study (21).  Light scattering is also purely a 
qualitative method with low resolution, so aggregates must be very large in comparison 
to monomers in order to be identified accurately (21).    
 Differential Scanning Calorimetry (DSC) is one of the work horse techniques of 
the drug development pipeline.  It can quickly assess the temperature stability of a drug 
in different formulations and requires very little protein, but does come with some 
significant drawbacks.  The technique measures the change in heat capacity of a 
protein in solution as the temperature is slowly increased from rather low (~10°C) where 
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the protein population is presumed to be almost completely folded, to a higher 
temperature (~100°C) where it is entirely unfolded.  This unfolding transition is 
characterized by an endothermic heat capacity peak whose maximum value, at the 
midpoint of the unfolding transition, is referred to by the temperature at which it occurs 
(Tm, or melting temperature).  The difference between the native and denatured state 
heat capacity baselines is called ΔCp.  This important quantity determines how 
drastically protein stability changes with temperature and is crucial for any sort of 
extrapolation of stability to room temperature or beyond (22-25).  Using these 
parameters, a complete thermodynamic description of protein unfolding can be 
obtained, allowing the determination of ΔG at any temperature (22-24). 
To thermodynamically analyze a DSC curve completely, an accurate 
determination of ΔCp must be acquired, which can be difficult if the protein unfolds 
irreversibly.  Reversibility is tested by scanning up to a temperature such that the 
protein is entirely unfolded, cooling it to near room temperature, and then rescanning 
the sample.  If unfolding is reversible, the rescan after cooling will perfectly replicate the 
original scan.  If the protein irreversibly unfolds, the rescan will, generally, be a flat line, 
as all of the protein is already unfolded.  For biologics, this poses a problem, as larger 
proteins like antibodies tend to almost exclusively unfold irreversibly and precipitate out 
of solution, which is seen as a sharp exothermic drop in signal in DSCs equipped with a 
coin-shaped sample cell.  While this still allows for a quick assessment of stability by the 
position of Tm, it makes a more detailed analysis of the curves difficult, if not impossible.  
Besides the inability to determine ΔCp, the precipitation is so extreme that it can even 
affect the Tm, making the calculated values less reliable.  In instruments equipped with a 
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capillary cell, the exothermic drop in signal is not observed (25, 26), and the full 
denaturation process can be observed and studied, although deconvoluting the curves 
into their respective kinetically controlled transitions characterized by both a calorimetric 
and activation enthalpy can be highly complex.   
 Isothermal Chemical Denaturation (ICD) refers to the denaturation of a protein 
with large concentrations of a chemical denaturant, most commonly urea or Guanidine 
Hydrochloride (GdnHCl).  Monitoring the populations of folded and unfolded protein 
(usually through intrinsic fluorescence) at varying denaturant concentrations can be 
used to calculate ΔG values for protein in different formulations (27, 28).  Conducting 
ICD experiments at increasing protein concentrations and comparing the calculated ΔG 
values can provide information on the aggregation propensity of a given protein-
formulation pair, as well as what conformation the protein aggregates in(29).  Since 
aggregation is a concentration dependent process, an increase in ΔG with increasing 
protein concentration indicates that the protein aggregates in the native state, while a 
decrease indicates denatured state aggregation, and no change points towards a lack 
of significant amounts of aggregation(29).   
ICD has long been a useful technique for studying protein stability due to the 
empirical observation that there is a linear relationship between ΔG and protein 
concentration, making the determination of ΔG⁰, the stability of the protein in no 
denaturant, a simple matter(30, 31).  It can also be conducted at room temperature and 
doesn’t require the specialized equipment of other techniques, as the only necessary 
instrumentation is a fluorometer to monitor the concentration of protein in various states 
through intrinsic tryptophan fluorescence.   
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But certain experimental factors limit the utility of ICD in formulation 
development.  As with many of the techniques discussed in this work, it requires lower 
protein concentrations than those used in formulation.  Also, since it requires molar 
concentrations of denaturant, it can be difficult to test formulations with high ionic 
strengths or high excipient concentrations, as solubility limits become an issue.   
 Proteins are in constant equilibrium between different conformations (e.g. native 
and denatured states) but the population of unfolded states at lower temperatures is 
generally small, especially for stable proteins used as drugs.  This means that the rate 
of unfolding is very small, so much so that it can’t be measured directly under storage 
conditions.  But since unfolding is a kinetic process, the rate of unfolding increases with 
temperature, as can be seen in the sharp unfolding transitions of DSC thermograms.  
But in isothermal calorimetry, rather than scanning up in temperature as in DSC, the 
sample is held at an elevated temperature that is still well below the Tm.  This elevated 
temperature raises the unfolding rate to a measureable level which can be measured 
using an isothermal calorimeter such as the Thermal Activity Monitor (TAM) from TA 
instruments or a conventional DSC used in isothermal scan mode.  These calorimeters 
can precisely hold one temperature for long periods of time, allowing the measurement 
of very small amounts of heat absorbed and released from the sample.  Plotting this 
“heat flow” as an evolution of time and fitting the data enables extraction of rate 
constants for the processes taking place in the sample that contribute to the heat flow.   
IC is a promising technique for formulation development for numerous reasons.  
It can be conducted, and has a better signal-to-noise ratio, at formulation protein 
concentrations near 100 mg/mL as opposed to the lower concentrations used by other 
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techniques.  This means that the aggregation of the protein in question is measured in 
precisely the same chemical and physical environment as it is stored in.  IC also doesn’t 
utilize the harsh denaturation conditions used in DSC or ICD, so the observed 
denaturation and aggregation may more accurately reflect the processes occurring 
during storage at low temperatures.  IC also doesn’t have any limitation as far as 
requiring reversible processes or certain structural elements like tryptophans in order to 
collect accurate data.  
 
Antibody Structure 
 Antibodies (specifically IgG1 class) are one of the key molecules of the immune 
system, binding to pathogens and marking them 
for destruction by other immune cells.  They have 
a characteristic “Y” shape composed of two 
antigen-binding (Fab) fragments and one 
crystallizable (Fc) fragment which come together at 
the “hinge” region (2).  Each ~150 kDa antibody is 
symmetrical and is composed of two identical light-
heavy chain pairs.  Each Fab consists of a 
complete light chain and the VH and CH1 domains 
of the heavy chain, with the complementarity 
determining region (CDR) which determines antigen binding located at the tip of each 
Fab, involving both light and heavy chain regions (2). The Fc region, which dimerizes 
the light-heavy chain pairs, is composed of the CH2 and CH3 regions of the heavy 
Figure 1-1. Structural features 
of an IgG monoclonal antibody. 
Domains making up the heavy 
chain (CH) are shown in dark 
blue, and light chain domains 
(CL) are shown in light blue (2).  
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chain (2). The heavy-light chain pairs are held together by disulfide bonds and are 
extensively glycosylated, particularly the CH2 domain, which further increases their 
complexity and can make production of homogeneous drug molecules difficult (2).  
These structural features are shown in Figure 1-1.  
VRC07-523LS 
 Human Immunodeficiency Virus (HIV) is one of the great public health problems 
of modern times, but development of an effective vaccine has so far been unsuccessful.  
While treatment with antiretroviral and other drugs has dramatically increased the post-
HIV infection lifetimes of patients, a vaccine that could prevent infection outright would 
be of great benefit.  Therapeutic vaccines are a promising tool to prevent HIV-infection 
in high-risk individuals.  The idea behind therapeutic vaccines is rather than convey 
immunity by “training” the immune system to recognize a particular pathogen, the 
body’s immune system is boosted by an infusion of antibodies specific to the virus of 
interest to block infection.  Treatment of at risk individuals with these anti-HIV antibodies 
during periods when the risk of transmission is high could prevent infection, such as 
treatment of a child to block mother-to-child transmission during birth.   
 VRC07-523LS is one such therapeutic vaccine in development at the Vaccine 
Research Center (VRC) and the National Institutes of Health.  VRC07-523LS is a clonal 
relative of VRC01, one of the first therapeutic HIV vaccines developed at the VRC (32).  
VRC01 was isolated from the blood of a donor who was a slow HIV progressor, having 
maintained low HIV-1 RNA loads in serum without the use of antiretroviral drugs for 
over 18 years (32).  It binds to the CD4 binding site of gp120 and blocks further infection 
(32).  The VRC07 class of antibodies was identified through the sequencing of antibody-
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gene transcripts for the same donor’s B cells from whom VRC01 was isolated (32).  The 
researchers made various targeted structural modifications to the originally isolated 
VRC07 to increase potency and decrease autoreactivity, eventually resulting in the 
optimized molecule VRC07-523LS, which will hereafter be referred to as VRC07 for 
simplicity (32).  
 
Chapter 2.  Protein Aggregation 
 
Models of protein aggregation: Lumry-Eyring 
 Protein aggregation is problematic in most laboratory and industrial settings, and 
is therefore a subject of intense interest among researchers in a variety of fields.  It is 
generally defined as the process by which originally monomeric protein self-assembles 
into high-molecular weight species, or aggregates, with non-native secondary structure 
(33).  These aggregates are often high in β-sheet content, and their rate of formation is 
concentration dependent (33).  Theoretically, a protein can aggregate in any of its 
adopted conformations.  But by and large, the most common conformation from which 
aggregation proceeds is the denatured state, as unfolding exposes hydrophobic 
patches of the protein that can nucleate aggregation.   
 Irreversible denatured state aggregation is generally discussed using the simple 
scheme: 
𝑁 ↔ 𝑈 → 𝐴 
where N is the native state, U is the denatured state, and A is the aggregated state.  
This sort of two-step model, where the protein exists in equilibrium between two states, 
one of which can irreversibly aggregate, is known as the Lumry-Eyring model of 
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aggregation (34).  In the case of native state aggregation, the irreversible conversion to 
A occurs from N.  If the protein populates a partially denatured state, and this state 
undergoes irreversible aggregation, then the model involves two equilibria between N 
and U with the partially denatured state, plus one irreversible step from the partially 
denatured state.  Applications of Lumry-Eyring models to different types of protein 
aggregation will be discussed in more detail in Chapter 4 of this manuscript, but will be 
briefly described here. 
Thermodynamics of Protein Aggregation 
 Although proteins that undergo irreversible aggregation tend to do so from the 
denatured state, some proteins can undergo native state aggregation under certain 
conditions.  Proteins that naturally form oligomers are a useful model to study this 
phenomena, such as the HIV-1 protease, which forms a dimer in the native state that 
dissociates upon unfolding (35).  Since aggregation generally is thought to be caused 
by the exposing of hydrophobic groups upon partial or complete unfolding, native state 
aggregation is rare.  Also, since the interactions that cause native state aggregation 
tend to be driven less by hydrophobicity, this aggregation tends to be at least partially 
reversible (35).  Native state aggregation pushes the equilibrium to the left, towards the 
native state, increasing ΔG with protein concentration proportionally to the level of 
native association. 
 Since unfolding of a protein, even just a part of it, exposes hydrophobic groups 
which can nucleate aggregation, partially denatured or denatured state aggregation are 
the most common observed types.  The main reason that more proteins that aggregate 
in the partially denatured state are not observed is likely due to the fact that stable 
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unfolding intermediates are rarer than simple two-state unfolding equilibria.  For large, 
multi-domain proteins like monoclonal antibodies, however, aggregation of a partially 
denatured state is a significant concern.  Aggregation in the partially denatured state 
pushes the equilibrium towards that state and away from the native and denatured 
states.  This means that ΔG decreases with protein concentration for the 𝑁 ↔ 𝑃 
transition, where P is the partially denatured state, and ΔG increases with protein 
concentration for the 𝑃 ↔ 𝑈 transition.  If the partially denatured aggregate does not 
dissociate upon unfolding, then ΔG will only increase for the first transition while being 
independent of protein concentration for the second transition from partially denatured 
to fully denatured.   
 Fully denatured protein is generally the most prone to aggregation due to the 
large number of hydrophobic residues exposed upon unfolding.  Aggregation in the 
denatured state drives the equilibrium towards the unfolded state, decreasing ΔG for the 
unfolding equilibrium with protein concentration.   
 The conformational stability of a protein clearly effects its aggregation propensity, 
particularly the stability of the native state.  Since the native state is generally the least 
prone to aggregate of the available conformations, and a higher ΔG for the native-
denatured state equilibrium means a higher fraction of protein in the native state, this 
leads to a decrease in the available states that can lead to aggregates.  And since 
aggregates depopulate the native state, they have a direct effect on the conformational 
equilibrium.  This means that excipients often utilize one of two different strategies to 
minimize aggregation: either stabilizing the native state, or the denatured state in order 
to prevent it from transitioning to an aggregated state.  Increasing the stability of the 
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native state means that a greater fraction of protein is in the native state, and this 
conformation is less likely to aggregate than other conformations.  The native state is 
also generally the active state for biologics, so maximizing the population of protein in 
the native state also leads to maximal potency for the drug.  Stabilizing the denatured 
state can also prevent aggregation by increasing the fraction of protein in the denatured 
state instead of unwanted conformations.  This is usually accomplished by the addition 
of excipients like L-Arginine which associate with the denatured state to solubilize it and 
prevent it from transitioning to an irreversibly aggregated state.  While this approach 
successfully curtails aggregation, it also decreases ΔG for the first (unfolding) transition 
due to the association with the denatured state.  This means that it is only effective if the 
stability of the protein without excipient is high enough that it can tolerate a slight 
decrease in stability in order to prevent aggregation.   
Kinetics of Protein Aggregation 
Since protein aggregation, particularly in the partially or fully denatured state, is 
an irreversible process, it is not governed by equilibrium thermodynamics.  Instead, it is 
a kinetic process with rate constants that describe the speed with which a particular 
conformation becomes aggregated.  These rate constants increase with temperature 
and, since aggregation is a concentration dependent phenomenon as discussed 
previously, they also increase with protein concentration.  The simplest kinetic scheme 
for protein aggregation is a one-step irreversible reaction from some native state N to an 






Where k is the rate constant describing the speed of the reaction.  The disappearance 
of N over time can be described by a single-exponential (first-order) rate equation: 
𝑁 = 𝑁0𝑒
−𝑘𝑡 
Where N0 is the initial concentration of N.  And since there are only two possible states 
for the protein, then the equation describing the concentration of A over time is simply: 
𝐴 = 𝑁0 − 𝑁0𝑒
−𝑘𝑡 
As any disappearance in N directly corresponds to an increase in A.  Expressing the 
amounts of protein in each state in terms of fractions of the total population rather than 
individual concentrations further simplifies the above expressions, as assuming the 
population is entirely in the native state at the start of the reaction, N0 can be replaced 
by 1.   
But this one-step scheme is too simple to describe most aggregation reactions.  
A better model is one that is similar to the Lumry-Eyring model discussed previously for 





→  𝐴 
Where ku is the overall rate of unfolding, and kagg is the rate of irreversible aggregation 
from the unfolded state.  The equations for this simplified model are similar to the one-
step model above:  
𝐹𝑁 = 𝑒
−𝑘𝑢𝑡 




𝐹𝐴 = 𝐹𝑈(1 − 𝑒
−𝑘𝑎𝑔𝑔𝑡) 
Where FN, FU, and FA are the fraction of protein in the native, unfolded and aggregated 
states respectively.  Since the rate of accumulation of protein in the aggregated state is 
dependent on both the rate of aggregation and the rate that protein unfolds, due to the 
fact that aggregation can only occur from the unfolded state, the behavior of the overall 
system depends on the relative magnitudes of the unfolding and aggregation rates.  If 
the rates are similar, then unfolding and aggregation are well separated processes in 
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time, each described by their respective rate constants, as 
shown in Figure 2-1A.  But if the aggregation rate is much 
faster than the unfolding rate, then the protein aggregates 
as soon as it unfolds and the overall process is described by 
a single rate constant, as shown in Figure 2-1B.  The 
behavior becomes even more complex in an experimental 
context, such as in an isothermal calorimetry measurement.  
In such an experiment, the total heat associated with the 
unfolding and aggregation of the protein sample is 
proportional to the concentration of unfolded and 
aggregated protein and the heat associated with each 
process: 
 
Where v is the sample volume, ΔHu is the enthalpy of 
unfolding (endothermic), and Qagg is the heat of irreversible 
aggregation (exothermic).  The concentration of unfolded 
and aggregated protein can be rewritten in terms of the total 
protein concentration (PT) and the fraction unfolded and 
fraction aggregated as: 
The heat can then be normalized by the sample volume and 
the total protein concentration to express the heat only in 
Figure 2-1. The 
relative magnitude of 
the rate constants 
effects the separation 
of unfolding and 
aggregation. A) The 
fraction unfolded and 
aggregated for a 
protein with equal 
unfolding and 
aggregation rates (1.5 
days-1). The processes 
are well separated, 
with aggregation 
lagging behind 
unfolding. B) When 
the aggregation rate is 
much faster than the 
unfolding rate, the 
fraction unfolded and 
fraction aggregated 
curves overlap and the 
overall process is 






Heat = 𝑣∆𝐻𝑢[𝑈] + 𝑣𝑄𝑎𝑔𝑔[𝐴𝑔𝑔] 
𝐻𝑒𝑎𝑡 = 𝑣∆𝐻𝑢[𝑃𝑇]𝐹𝑢 + 𝑣𝑄𝑎𝑔𝑔[𝑃𝑇]𝐹𝑢𝐹𝑎𝑔𝑔 
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terms of the fraction unfolded and fraction aggregated and the heats associated with 
each process: 
Fu and Fagg can then be expressed in terms of the rate of unfolding and aggregation as 
discussed above: 
Since the TAM actually measures the heat flow, or dQ/dt of a sample, we take the 
derivative of this above equation to get the equation used to model and fit isothermal 
calorimetry data: 
Based on this equation, an isothermal calorimetry curve for a protein that unfolds and 
aggregates will be composed of an endothermic unfolding portion followed by an 
exothermic aggregation portion of the curve.  The relative magnitudes of the rates and 
heats of unfolding and aggregation to each other will determine the final shape. In 
general, the heat of unfolding determines the magnitude of the endothermic portion of 
the curve while the rate of unfolding determines the steepness of that portion of the 
curve.  On the other hand, the heat of aggregation determines the magnitude of the 




= ∆𝐻𝑢𝐹𝑢 + 𝑄𝑎𝑔𝑔𝐹𝑢𝐹𝑎𝑔𝑔 
𝑄 = ∆𝐻𝑢(1 − 𝑒
−𝑘𝑢𝑡) + 𝑄𝑎𝑔𝑔(1 − 𝑒







− (𝑘𝑢 + 𝑘𝑎𝑔𝑔)𝑄𝑎𝑔𝑔𝑒
−(𝑘𝑢+𝑘𝑎𝑔𝑔)𝑡 
Figure 2-2. Simulated data in which ΔHu and Qagg 
are approximately equal.  The location and width 
of the exothermic aggregation peak is determined 
by the magnitude of the two rate constants in 
proportion to each other. The value for ku for each 
curve is 1 day-1, while kagg is varied between 0.5 
and 2 days-1. 
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portion of the curve is.  Based on the relative 
magnitudes of the various parameters, a variety 
of curve shapes can be observed.  If the 
unfolding enthalpy and aggregation heat are 
similar, then the ratio of the unfolding and 
aggregation rate constants determines the 
location and width of the exothermic 
aggregation portion of the curve, as shown in 
Figure 2-2.  
If the aggregation rate is much higher than the 
unfolding rate, then the heat flow equation can 
be simplified to a single exponential:   
𝑑𝑄
𝑑𝑡
= 𝑘𝑢(∆𝐻𝑢 + 𝑄𝑎𝑔𝑔)𝑒
−𝑘𝑢𝑡= 𝑘𝑢𝑄𝑡𝑜𝑡𝑎𝑙𝑒
−𝑘𝑢𝑡 
Where the total heat is a sum of the enthalpy of unfolding and the heat of aggregation. 
A curve with a kagg 25 times greater than ku is shown in comparison to a curve with 
equal unfolding and aggregation rates, along with single exponential fits, in Figure 2-3.   
 
 
Chapter 3. Temperature Dependence of Rate Constants 
 
Rate constants, much like equilibrium constants, are temperature dependent.  
While equilibrium constants can be described by the free energy of the equilibrium or its 
Figure 2-3. The relative 
magnitudes of the rate constants 
effects the shape of the heat flow 
curve. Simulated data for the case 
in which ku = kagg is shown in red 
with the associated single 
exponential fit as a solid line, and 
the case where kagg = 25* ku is 
shown in blue. The blue data is 
well described by a single 




associated enthalpy and entropy, rate constants can be described by the free energy of 
activation and the enthalpy and entropy of activation (indicated by a dagger superscript, 
†). The temperature dependence of rate constants can be described by: 







But the temperature dependence goes further, as it has been well established that both 
the enthalpy and entropy are temperature dependent due to the existence of a heat 
capacity difference between the native and denatured states.  The temperature 
dependence of the activation enthalpy and entropy can be written as: 
∆𝐻† = ∆𝐻𝑟𝑒𝑓
† + ∆𝐶𝑝









Using these equations, the effect of the 
different parameters on the rate constant 
over a wide temperature range can be 
observed.  As can be readily seen from the 
equations, the existence of a ΔCp† leads to 
non-linear Arrhenius plots, as shown in 
Figure 3-1.  Examining the figure, it is readily 
apparent that while the rate constant is the 
same for all three curves at Tm, and the 
curves can be considered linear over short 
temperature stretches, especially at higher 
temperatures, the effect of a difference in ΔCp† has a large effect on the rate constant at 
lower temperatures.  This effect is crucial to consider when extrapolating rate constants 
to storage temperatures, since the effect of ΔCp† is greater at lower temperatures.  
These lower temperatures are already very far away from Tm, which is generally the 
reference temperature that data is extrapolated from.  Assuming linearity can lead to 
vast underestimations in the rate constant at storage temperatures due to this effect.  
An example of how much this ΔCp† induced curvature can affect the value of the rate 
constant at lower storage temperatures is shown in the simulated data using typical 
parameters for globular proteins in Figure 3-2. While the blue protein has a Tm that is 20 
degrees higher than the red, the 2 kcal/K/mol difference in their ΔCp† leads to the red 
protein being more stable with a smaller rate constant at a storage temperature of 4°C 
by almost seven orders of magnitude.  This clearly illustrates the large effect that small 
Figure 3-1. The magnitude of ΔCp† 
affects the curvature of the rate 
constant temperature dependence 
curve, particularly at low 
temperatures. Arrhenius plot showing 
the natural log of the rate constant 
versus 1/T for simulated protein data 
in which all parameters are the same 
between curves except for ΔCp† 
varying between 2 and 4 kcal/K/mol.  
29 
 
changes in ΔCp† can have on the values of rate 
constants when extrapolating to low 
temperatures, as well as the pitfalls of assuming 
linearity over a wide range of temperatures in an 
Arrhenius plot, as ΔCp† causes pronounced 
curvature over wide temperature ranges.  Since 
most measurements, even those presented in 
this work using isothermal calorimetry below Tm, 
are conducted well above the storage 
temperatures that data is extrapolated to, an 
understanding of ΔCp† is crucial for making 
accurate predictions.  It is also crucial that any 
experimental determination of ΔCp† be extremely 
accurate, as small changes in its value can have very large effects on rate constants at 
low temperatures. 
 
Chapter 4. Conformational stability and self-association equilibrium in 
biologics 
 
This chapter was published in Drug Discovery Today (Clarkson et. al. 2015). 
Introduction 
The expected growth of biologics during the next years and their transformation 
from drugs administered mainly in hospital settings to drugs self-administered by 
Figure 3-2. Small differences in 
ΔCp† can lead to large changes in 
the rate constant at low 
temperatures. Simulated data for 
three proteins with Tm values of 
40, 50, and 60°C and ΔCp† values 
of 2, 3, and 4 kcal/K/mol for the 
red, orange, and blue curves 
respectively. The rate constant is 
shown versus T instead of lnk vs 
1/T for clarity. All other 




patients, requires the fulfilment of strict safety and stability conditions.  The long term 
stability of biologics is a function of diverse physical and chemical factors that require 
different solutions.  Among them, it becomes necessary to identify conditions that 
maximize the structural stability of the native state and prevent aggregation or other 
undesirable processes (36-39).  Maximizing structural stability and minimizing 
aggregation tendencies involve decisions in at least two different development stages: 
the selection of the protein variants with the top stability/aggregation profiles; and, the 
identification of the solution conditions (formulations) that maximize stability and 
minimize aggregation.  These decisions will be facilitated by a better understanding of 
the existing linkage between conformational and self-association processes. 
 
Conformational Equilibrium in 
Proteins 
Proteins exist in 
equilibrium between the native, 
partially denatured and fully 
denatured conformations.  Even 
though there is an astronomical 
number of partially denatured 
(also referred to as partially 
folded) conformations, the vast 
majority never becomes 
populated.   In fact, the 
native/denatured state equilibrium 
Figure 4-1.  Typical protein denaturation 
situations encountered in the laboratory.  The top 
panel illustrates the classical two-state situation in 
which protein denaturation occurs without the 
presence of partially denatured conformation.  
This situation is mostly observed for single 
domain proteins or multi-domain proteins with 
highly cooperative inter-domain interactions.  The 
bottom panel illustrates the situation in which 
denaturation occurs with the presence of a 
significantly populated partially denatured state.  





of most single-domain proteins can be accounted for by the two-state model, in which 
the population of partially denatured conformations is negligible (40).  Multi-domain 
proteins may exhibit partially denatured conformations corresponding to states in which 
some domains are unfolded while the others remain folded (41).   Figure 4-1 illustrates  
two commonly observed situations.  The top panel represents the two-state situation in 
which the native and fully 
denatured conformations are 
the only ones that become 
significantly populated.  The 
bottom panel represents the 
situation in which a partially 
denatured conformation 
becomes populated in 
addition to the native and fully 
denatured states.  The 
partially denatured state 
usually originates from the 
unfolding of the least stable 
domain.  In all cases, the 
stability of a protein or a 
structural domain is 
determined by the Gibbs 









5.5 0.01          
6.8 0.001        
8.2 0.0001      
9.6 0.00001    
10.4 0.000001   
32 
 
characteristic of each structure.   The population or fraction of denatured protein or 










                                       (4-1) 
A large and positive ∆G minimizes the fraction of denatured protein.  Table 4-1  
shows a look up table with characteristic ∆G values and the corresponding populations 
of denatured protein. The percent of denatured protein is simply the fraction denatured 
multiplied by 100.  Also, the actual concentration of denatured protein is simply the total 
protein concentration multiplied by the fraction denatured.  For example, in a 100mg/mL 
protein solution with a structural stability of 8 kcal/mol the concentration of denatured 
protein is 0.1µg/mL.  In protein engineering or formulation development, a common goal 
is to optimize the structural stability of the protein, which is equivalent to maximizing ∆G.  
There are two techniques capable of measuring Gibbs energies and therefore able to 
provide a window into the conformational equilibrium of a protein: Differential Scanning 
Calorimetry (DSC) and Isothermal Chemical Denaturation (ICD).  DSC induces protein 
denaturation by increasing the temperature of the solution (24, 42, 43), whereas ICD 
induces protein denaturation by the addition of a chemical denaturant, most commonly 
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urea or guanidine 
hydrochloride (29-31, 44-
46).  In both cases, the 
necessary requirement 
for ΔG determination is 
that the experimental 
measurement is 
performed under 
reversible conditions.  
This condition is tested 
by scanning the same 
sample twice or diluting the denatured concentration and recovering the original state. 
Figure 4-2 illustrates the type of data obtained by DSC and ICD for a protein 
characterized by the presence of two cooperative domains.  In both cases, analysis of 
the data permits determination of ΔG1 and ΔG2 and their subsequent analysis (24, 29-
31, 42-46).  
Figure 4-2. Differential scanning calorimetry (DSC) and 
isothermal chemical denaturation (ICD) allow 
measurement of the folding/unfolding reaction of a protein 
and determination of the Gibbs energy of stability (ΔG) for 
each step. Folding/unfolding thermodynamics can only be 





Thermodynamic Linkage Between Conformational Equilibrium and Self-
Association 
Three immediate 
aggregation scenarios can 
be envisioned from the 
conformational equilibrium 
situations shown in 
Figure 4-1.  The first case 
is the one in which the 
native state aggregates, 
the second case is the 
one in which the partially 
denatured state 
aggregates, and the third 
case the one in which the 
denatured state 
aggregates.   
 
Case 1:  Native State Aggregation 
Figure 4-3 illustrates the situation in which native state aggregation is present.  
In this case the equilibrium will be shifted to the left, ΔG of the denatured and partially 
denatured states will increase and, consequently, the stability of the native state will 
increase.  If this situation occurs, the measured ΔG usually referred to as apparent ΔG is 
given by (47): 
Figure 4-3.  Self-association or aggregation of the 
native state is characterized by an increase in ΔG upon 
increasing protein concentration.  The inset shows the 
example of the HIV-1 protease which is a dimer in the 
native state and dissociates upon unfolding.  
Denaturation experiments were performed using a 
linear gradient of guanidine hydrochloride from 0 to 5.5 
M.  The buffer was 10 mM sodium formate, pH 3.4.  The 
final concentration of protease was varied from 0.4 to 12 
uM.  The exact concentration was determined from the 
absorbance at 280 nm using an extinction coefficient of 
25,530 M-1 cm-1 (3). Gold arrows indicate direction of 






𝑜 + 𝑅𝑇𝑙𝑛(1 + 𝑗𝐾𝑁,𝑗[𝑁]
𝑗−1)                                         (4-2) 
 
Where ∆𝐺𝑜
𝑜 is equal to the value of the Gibbs energy extrapolated to zero protein 
concentration (in practice, a concentration low enough at which aggregation is not 
present).  Equation 4-2 indicates that native state aggregation will cause the measured 
Gibbs energy to increase as a function of protein concentration and that the magnitude 
of the increase is proportional to the aggregation constant and the average size of the 
aggregates.  For the specific case in which the native state forms a dimer (j = 2), 
equation 4-2 has an exact solution that can be expressed in terms of the total protein 
concentration as demonstrated before for the HIV-1 protease (3) (see inset in Figure 4-
3).  In this case, it is possible to determine the dimerization constant which under the 
conditions in the figure is 1.6 x 10-8 M.   For arbitrary degrees of oligomerization, there 
are no exact solutions for KN,j but the fraction of aggregated protein can be calculated 













                                      (4-3) 
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Where  ∆∆𝐺 = ∆𝐺𝑎𝑝𝑝 − ∆𝐺𝑜
𝑜.  In 
general, if experiments are 
performed at different protein 
concentrations, an increase in 
the measured ΔG with protein 
concentration is indicative of 
native state aggregation or 
oligomerization.  
 
Case 2:  Partially Denatured 
State Aggregation 
In some situations, partially denatured conformations have a higher tendency to 
aggregate than the native or denatured states.  The situation is illustrated in Figure 4-4.  
In this case, the first transition, corresponding to the transition from monomeric native to 
self-associated partially denatured states is shifted down upon increasing protein 
concentration whereas the second transition, corresponding to the transition from the 
self-associated partially denatured to monomeric fully denatured state is shifted up upon 
increasing protein concentration.  Experimentally, this situation has been observed with 
recombinant human growth hormone (rHGH) at low pH (1).  rHGH is a monomeric 
Figure 4-4.  Partially denatured conformations 
might have a higher tendency to aggregate than the 
native or fully denatured state, in which case 
aggregation occurs when the partially denatured 
state becomes populated.  In this case, dissociation 
occurs upon full denaturation.  This behavior is 
exhibited by recombinant human growth hormone 
at low pH (1). Gold arrows indicate direction of 












denaturation.  It 
must be noted 
that if the 
aggregated 
partially 
denatured state were the end point of the denaturation transition, it will result in only the 
destabilization of the native state.   In the DSC experiments, as shown in Figure 4-5, 
the Tm of the first transition decreases with rHGH concentration whereas the Tm of the 
second transition increases with rHGH concentration.  A similar behavior is observed in 
chemical denaturation experiments.  In this case the first transition occurs at lower 
denaturant concentrations and the second transition at higher denaturant 
concentrations.  It is worth mentioning, that several monoclonal antibodies exhibit two 
chemical denaturation transitions.  If this is the case, an assessment of native state 
aggregation requires that the two transitions exhibit higher ΔG values upon increasing 
protein concentration. 
Figure 4-5.  Partially denatured state aggregation shifts both 
transitions in complete protein unfolding. Left panel: The heat 
capacity function of recombinant human growth hormone at pH 3 
(10 mM glycine buffer) as reported by Kasimova et al (1).  The blue 
curve corresponds to a concentration of 10mg/mL and the green 
curve to a concentration of 2mg/mL.  Upon increasing 
concentration (blue curve) the first transition occurs at a lower Tm 
and the second transition occurs at a higher Tm.  Right panel: 
simulation of expected chemical denaturation of recombinant 
human growth hormone.  Upon increasing protein concentration 
(blue curve) the first transition is shifted to lower denaturant 
concentrations (lower ΔG) and the second transition to higher 





Case 3:  Denatured State Aggregation 
Figure 4-6 
illustrates the situation in 
which denatured state 
aggregation is present.  In 
this case the equilibrium 
will be shifted to the right, 
ΔG will decrease and the 
stability of the native state 
will decrease.  If this 
situation occurs, the 




𝑜 − 𝑅𝑇𝑙𝑛(1 +
𝑗𝐾𝑁,𝑗[𝑁]
𝑗−1)                                         
(2) 
 
Figure 4-6.  Denatured state aggregation will pull the 
equilibrium to the right and decrease ΔG as the protein 
concentration increases.  Gold arrows indicate direction 
of equilibrium shift. The decrease in ΔG indicates a lower 
stability of the native state.  The inset illustrates this 
situation by depicting the concentration dependence of 
ΔG for Cetuximab in urea denaturation experiments. 
Denaturation was performed using linear gradient of urea 




Previously, this behavior has been reported for Cetuximab in urea denaturation 
experiments (47).   ΔG decreased from about 9 kcal/mol at 24 µg/mL to 7 kcal/mol at 
180 µg/mL consistent with denatured state aggregation.  In those experiments, urea 
was able to resolve only one transition; however, subsequent experiments performed 
with guanidinium hydrochloride (GndnHCl), a more potent chemical denaturant, were 
able to resolve two transitions.  However, only the first transition exhibited a consistent 
decrease in ΔG upon increasing antibody concentration suggesting that the aggregating 
conformation is the partially denatured state emerging from the first transition.  The 















Figure 4-7.  Situation in which a partially denatured state exhibits a 
tendency to aggregate.  In this case, full denaturation does not lead 
to dissociation as in Figure 4-4.  Even though the denatured high 
stability domain does not exhibit an intrinsic tendency, the entire 
protein remains aggregated through the denatured low stability 
domain.  In this situation, the ΔG of the first transition decreases with 
protein concentration but the second one remains constant.  This 
appears to be the case observed for the guanidinium hydrochloride 
denaturation of Cetuximab obtained at 12 and 48 µg/mL (inset in the 
figure). Denaturation was performed using linear gradient of guanidine 





aggregation process, it should not be confused with the situation observed with rHGH in 
which full denaturation leads to dissociation of the oligomeric intermediates.  This 
dissociation is seen as a ΔG increase for the second transition upon increasing protein 
concentration.  If the Gibbs energy of the second transition remains unchanged, it 
strongly suggests that the high stability domain does not have an intrinsic aggregating 
tendency.  In this case, measures to prevent aggregation should be aimed towards the 
least stable domain. 
 
Conclusions 
The analysis presented here indicates that different modes of aggregation affect 
differently the conformational equilibrium of a protein.  Since the conformational 
equilibrium and its concentration dependence can be measured by DSC or ICD, this 
analysis can provide valuable information in the identification of better protein variants 
or better formulations.  Preventing aggregation processes that are linked to the 
conformational equilibrium of a protein requires: 1) Minimizing the concentration of 
aggregating species; and, 2) Minimizing the self-association constant of the aggregating 
species.  This task can be accelerated by a quantitative knowledge of the 
conformation/self-association equilibrium. 
 




As detailed in Chapter 4, chemical denaturation can be used to determine 
whether a protein primarily aggregates in the native or denatured state.  Comparing the 
change in ΔG with protein concentration for different buffers can also be a useful tool for 
formulation development and optimization. An ideal formulation should have a large ΔG 
with very little dependence on the protein concentration such that at formulation 
concentrations of 100 mg/mL or greater the protein is maximally stable and shows 
minimal propensity to aggregate.  While excipients like L-Arginine lower the free energy 
of the native state through their interactions with the denatured state, this interaction 
also greatly decreases the concentration dependence of the free energy through 
mitigating aggregation, leading to greater stability at formulation protein concentrations 
in some cases.  It is important to note that if the destabilization of the native state is 
great enough, the value of ΔG at high protein concentrations may still be lower than for 
other formulations with 
more of a concentration 
dependence.  Chemical 
denaturation studies at a 
range of protein 
concentrations were 
conducted with VRC07 in 4 
buffers which were 
identified as potential 
formulation buffers at the 























Figure 5-1. ΔG values for VRC07 at different protein 
concentrations using GdnHCl as denaturant. Values 
were calculated using parameters obtained by a global 
fit of concentration dependence data with a 0-6.4M 
gradient of GdnHCl. 
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of VRC07: buffer/formulation 1 (50 mM histidine, 100 mM NaCl, pH 6.8), 
buffer/formulation 2 (50 mM histidine, 100 mM NaCl, 5% w/v sucrose, pH 6.8), 
buffer/formulation 3 (50 mM histidine, 100 mM NaCl, 5% w/v sorbitol, pH 6.8), and 
buffer/formulation 4 (50 mM histidine, 50 mM NaCl, 5% w/v sucrose, 2.5% w/v sorbitol, 
pH 6.8).  These experiments showed very little difference in stability between the four 
buffers, as shown by their similar ΔG values at different protein concentrations, as well 
as a decrease in stability with increasing protein concentration indicating denatured 
state aggregation (Figure 5-1).  These ΔG values were calculated using parameters 
obtained from global fits of the concentration dependence data for each buffer.  Since 
these global fits rely on numerous parameters obtained from the data, not all of which 
are always reliable to determine, it is often useful to analyze chemical denaturation data 
using the concentration at which half of the protein is denatured, or C1/2, as this value is 
less dependent on the shape of each individual curve and the resulting native and 
denatured baselines and is therefore extremely reliable and replicable between 
experiments.  The reliability of these other parameters, such as the slope of the 
transition region or m-value, can usually 
be improved by obtaining more data 
points in each denaturation curve, 
although this requires significantly more 
protein for each curve.  Figure 5-2 
shows a plot of C1/2 vs protein 
concentration which clearly shows that 



























Figure 5-2. C1/2 vs protein concentration 
for VRC07 as measured using GdnHCl as 
denaturant. Conditions are same as 
Figure 5-1.  
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with the largest C1/2 values at every tested protein concentration, while buffer 1 is the 
worst of the set. 
DSC studies are also useful in 
formulation development as detailed in 
Chapter 1, but investigations of 
monoclonal antibody stability are often 
impeded by the irreversibility of antibody 
thermal unfolding transitions, precluding 
a full thermodynamic analysis of the 
curves and even affecting their shape 
and properties.  To attempt to address 
this issue, various DSC experiments 
were conducted with VRC07 looking at 
the effect of pH and low concentrations 
of GdnHCl on the reversibility of 
unfolding transitions.    At formulation 
pH (6.8), the DSC thermogram for 
VRC07 shows one peak centered at 
70°C, but when the pH is decreased to 
3.5, three distinct transitions appear as 
shown in Figure 5-3A.  Reversibility for 
a transition was tested by scanning to a 
temperature just past the Tm, then 
Figure 5-3. Decreasing pH to 3.5 reveals 
three separate transitions in VRC07 
thermal unfolding. A) DSC thermograms 
for 1 mg/mL VRC07 in pH 6.8 (20 mM 
sodium phosphate) and 3.5 (50 mM 
sodium formate, 50 mM NaCl) buffer at 
1°C/min scan rate.  The scan at pH 6.8 
has one peak at 70.8°C, while the scan at 
pH 3.5 has peaks at 40.3, 55.6, and 
90.6°C. B) DSC scan showing the 
reversibility of each transition for 1 mg/mL 
VRC07 at pH 3.5. A full scan is shown for 
reference, after which the instrument was 
cleaned and reloaded with protein and the 
reversibility of each transition was tested 





cooling the instrument back to the starting 
temperature, then scanning all the way 
through the given transition.  If the 
transition is reversible, the rescan will 
contain a peak at that temperature, while 
an irreversible transition will show no 
signal upon rescanning.  As shown in 
Figure 5-3B, the first transition is fully 
reversible, the second transition is 
irreversible, and the third transition 
appears to be partially reversible judging 
by the decreased Tm and enthalpy of the 
peak upon rescanning.  Interestingly, in 
appearance of three transitions at pH 3.5 
was also observed for two other tested 
mAbs: VRC01LS and Cetuximab.  
VRC01LS is another therapeutic HIV 
Figure 5-4. Decreasing pH to 3.5 
reveals three separate transitions in 
VRC01 thermal unfolding. A) DSC 
thermogram for 1 mg/mL VRC01 in 
formulation buffer (pH 5.8, 25 mM 
sodium citrate, 50 mM NaCl, 50 mM 
L-Arginine) at 1°C/min scan rate.  The 
one peak is centered at 71.2°C. B) 
DSC scan showing the reversibility of 
each transition for 1 mg/mL VRC07 at 
pH 3.5. A full scan is shown for 
reference, after which the instrument 
was cleaned and reloaded with 
protein and the reversibility of each 
transition was tested as described in 
the text. The three peaks are centered 
at 37, 59.3, and 97°C. The first and 





antibody developed at the NIH as briefly 
discussed in Chapter 1 and 6 of this work, 
while Cetuximab (trade name Erbitux) is an 
anti-EGFR antibody used in the treatment 
of various cancers (48).  Both antibodies, 
particularly Cetuximab, are somewhat 
difficult to formulate.  They also both have 
one unfolding transition at their formulation 
pH, but show three distinct transitions at pH 
3.5 where the first and third transition are at 
least somewhat reversible.  These 
thermograms are shown in Figure 5-4 
(VRC01) and Figure 5-5 (Cetuximab).  
 
Chapter 6. Long-Term Stability of 
an HIV-1 Neutralizing Monoclonal 
Antibody Using Isothermal 
Calorimetry. 
 
This chapter was published in Analytical 
Biochemistry (Clarkson et. al. 2018).  
Abstract 
Different factors affect the long term stability of monoclonal antibodies, among 
them denaturation or partial denaturation that is often followed by aggregation. 
Isothermal calorimetry is capable of quantifying the kinetics of denaturation/aggregation 
Figure 5-5. Decreasing pH to 3.5 
reveals three separate transitions in 
Cetuximab thermal unfolding. A) DSC 
thermogram for 1 mg/mL Cetuximab 
in formulation buffer (pH 7.5, 10 mM 
PBS) at 1°C/min scan rate.  The one 
peak is centered at 72.8°C followed 
by sample precipitation. B) DSC scan 
showing the reversibility of each 
transition for 1 mg/mL VRC07 at pH 
3.5. The three peaks are centered at 
43.6, 65, and 99.4°C. The first and 






of an antibody by measuring the heat that is released or absorbed by the process over a 
period of days or weeks, at temperatures below its denaturation temperature, Tm.  The 
denaturation/aggregation kinetics of the anti-HIV monoclonal antibody VRC07-523LS 
was measured by isothermal calorimetry at different concentrations in four different 
formulation buffers.  The measurements were performed at ten degrees below Tm, as 
determined by differential scanning calorimetry.  The formation of aggregates was also 
followed by size exclusion chromatography at 5°C, 25°C and 40°C over a period of 8-36 
weeks.  It was observed that the rates measured by isothermal calorimetry correlate 
quantitatively with those measured by size exclusion chromatography.  Since isothermal 
calorimetry experiments are performed over a period of ten days, it can become a 
valuable tool for a fast prediction of the best formulations. 
Introduction 
VRC01 is a highly potent CD4-binding monoclonal antibody that neutralizes 
~90% of HIV-1 strains with an IC50 of less than 50 µg/ml (49).  VRC07-523LS is a more 
potent clonal relative of VRC01 with 5 - 8-fold increased potency in vitro.  In nonhuman 
primates, VRC07-523LS prevented infection at a 5-fold lower concentration than VRC01 
(32).  These monoclonal antibodies are being developed by the Vaccine Research 
Center at the National Institutes of Health as immunotherapeutic agents for the 
suppression of acute HIV replication.  Nevertheless, future clinical use of VRC07-523LS 
or a similar monoclonal antibody, would require a dose on the order of 1 - 10mg of 
monoclonal antibody per kg of body weight.  Dosages of that magnitude require 
formulations with protein concentrations on the order of 100mg/mL or greater.   
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Formulating a monoclonal antibody at 100mg/mL or even higher concentrations 
gives rise to different challenges, including maintaining the structural stability of the 
antibody and minimizing any tendency to aggregate over long periods of time (13, 50).  
Identifying the best buffer and excipient conditions that maximize the long term stability 
of a monoclonal antibody is a major goal in biologics research.  It has become evident 
that not a single technique is sufficient for accurate decisions and that researchers need 
to rely on a battery of orthogonal measurements (51, 52).  Two types of techniques are 
generally available, techniques with the potential to quickly identify and predict the top 
formulation conditions (e.g., differential scanning calorimetry, differential scanning 
fluorometry, isothermal chemical denaturation) and techniques that actually measure 
aggregation after sample incubation for a relatively long period of time (e.g., size 
exclusion chromatography, light scattering).  For these techniques, the incubation times 
are usually reduced by accelerating any aggregation process by, for example, 
increasing the incubation temperature or stressing the sample in different ways (53-56).  
Often, results obtained from accelerated conditions do not correlate with aggregation 
pattern observed by SEC   especially at lower temperatures. 
In this paper, we have utilized isothermal calorimetry as a novel technique to 
measure the kinetics of denaturation/aggregation of a monoclonal antibody (VRC07-
523LS), and compare the results with those obtained by size exclusion chromatography 
(SEC).  Isothermal calorimetry, not to be confused with isothermal titration calorimetry 
(ITC), measures the rate of heat production or absorption associated with a 
spontaneous process occurring at a given temperature over relatively long periods of 
time, weeks or more.  For example, a protein that denatures and/or aggregates upon 
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storage at constant temperature, will absorb or release heat as a function of time in an 
amount proportional to the rate of increase in the concentration of denatured and/or 
aggregated protein.  Since the instrument is capable of measurements during days - to - 
weeks, isothermal calorimetry appears to be ideal to determine the rate of 
denaturation/aggregation at temperatures below the denaturation temperature (Tm) of 
proteins. 
In this paper, the kinetics of denaturation/aggregation of the monoclonal antibody 
VRC07-523LS has been measured by isothermal calorimetry at temperatures below Tm 
for four different formulation buffers.  Additional size exclusion chromatography 
experiments (SEC) indicate that the isothermal calorimetry experiments provided an 
identical rank order for the buffers considered in this study.   
 
Materials and Methods 
Proteins and Reagents:  The VRC/NIAID/NIH Vaccine Production Program (VPP) 
laboratory, Gaithersburg. MD, has developed optimized cell lines, upstream expression 
systems, and downstream purification processes for the VRC07-523LS monoclonal 
antibody.  Expression methods employ scalable, optimized fed-batch culture of stably-
transfected Chinese Hamster Ovary (CHO) DG44 cells with termination by culture 
supernatant harvest.  Purification by chromatography incorporates two orthogonal 
methods, a typical Protein A affinity capture step and a negative-capture with Capto 
Adhere (GE Healthcare), a multimodal polishing resin engineered specifically for Protein 
A-purified proteins.  Viral clearance is accomplished via low pH and viral filtration. 
Processing is concluded by diafiltration into formulation buffer and a final sterile 
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filtration. Four formulation buffers for VRC07-523LS were developed at the 
VRC/NIAID/NIH Vaccine Production Program (VPP) laboratory using design of 
experiment studies for optimizing pH, ionic strength, and buffer salt composition. 
Excipients which are either “Generally Regarded As Safe” (GRAS) by the FDA or have 
known acceptable safety profiles were screened using multiple techniques for 
determining colloidal and conformational stability to identify potential stabilizers.  The 
buffers identified were formulation 1 (50 mM histidine, 100 mM NaCl, pH 6.8), 
formulation 2 (50 mM histidine, 100 mM NaCl, 5% w/v sucrose, pH 6.8), formulation 3 
(50 mM histidine, 100 mM NaCl, 5% w/v sorbitol, pH 6.8), and formulation 4 (50 mM 
histidine, 50 mM NaCl, 5% w/v sucrose, 2.5% w/v sorbitol, pH 6.8).  Protein solutions at 
~150 mg/mL were dialyzed overnight against the desired buffer and diluted to the 
measuring concentration of 100, 50 or 25 mg/mL (isothermal calorimetry experiments), 
or ~1-2 mg/mL (DSC experiments).  Chemicals for buffer preparation were purchased 
from multiple vendors: L-Histidine (98%, CAS 71-00-1) from Acros Organics (New 
Jersey, USA), NaCl (Certified ACS/Crystalline, CAS 7647-14-5) from Fisher Scientific 
(Fair Lawn, NJ, USA), and sucrose (minimum 99.5%, CAS 57-50-1) and D-sorbitol 
(minimum 98%, CAS 50-70-4) from Sigma-Aldrich (St. Louis, MO, USA). 
Size Exclusion Chromatography:  High performance size exclusion chromatography 
(HPSEC) was used to monitor the levels of aggregation and fragmentation. Samples 
were analyzed using a ACTUITY BEH200 column (Waters) and 2X Phosphate Buffer 
Saline as the mobile phase. The monomer peak percentage was calculated as the 
monomer peak area divided by the total area of all protein related peaks. The peak area 
of all peaks eluting at times earlier than the monomer peak were reported as percent 
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aggregate.  Peaks eluting after the monomer peak, if present, were reported as percent 
fragment. 
Differential Scanning Calorimetry:  Thermal denaturation experiments were performed 
using both a VP-DSC microcalorimeter with a standard “lollipop” cell, as well as a VP-
DSC capillary cell microcalorimeter, from MicroCal/Malvern Instruments (Northamption, 
MA, USA) with scans from 10 to 100°C at a rate of 1°C/min.  Dialyzed protein was 
diluted to ~1 mg/mL (standard cell) and ~2 mg/mL (capillary cell), thoroughly degassed, 
then loaded into the calorimetric cell (~0.5 and ~0.12 mL in volume respectively).  The 
reference cell was filled with dialysis buffer.  Data collection and processing were 
performed using the software included with the instruments.  Data analysis was 
performed using the equations previously described in the literature for irreversible DSC 
protein denaturation (57, 58).  These equations were introduced into the DataFit 
software package (Oakdale Engineering, Oakdale, PA, USA). 
Isothermal Calorimetry:  Isothermal calorimetry experiments were performed using a 
TAM IV microcalorimeter system from TA Instruments (New Castle, DE, USA) equipped 
with six calorimeter channels as described previously (59, 60).  The experiments were 
conducted at 60°C.  Before samples were inserted, an initial 30-minute baseline was 
recorded.  Cylindrical glass ampoules were filled with 1 mL of protein solutions or buffer, 
and were hermetically sealed with crimp caps.  The ampoules were then loaded into 
each calorimetric channel to a position where they are allowed to equilibrate to the 
instrument temperature for 45 minutes before being lowered into the measuring 
position.  The heat flow, dQ/dt, was recorded as a function of time until all processes 
had gone to completion and the signal stabilized at a level close to zero (~ 8 days).  
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After removing the samples from the instrument, a final 30-minute baseline was 
recorded.  The baseline from the empty calorimeters were subtracted from the data 
collected for each.  The signal from the ampoule containing only buffer was subtracted 
from the heat flow from the sample and the differential signal was normalized per mole 
of protein.  The final signal was expressed as kcal/day/mol.  Data collection and 
processing of raw data were performed using the software included with the instrument.  
Analysis of the isothermal calorimetry data was performed using the equations 
described in this paper.  These equations were introduced into the DataFit software 
package (Oakdale Engineering, Oakdale, PA, USA). 
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Results and Discussion 
Differential Scanning Calorimetry.  Figure 6-1 shows the temperature dependence of 
the heat capacity function (Cp) of VRC07-523LS in the four buffers studied.  These 
experiments were performed in a standard “lollipop” shaped cell microcalorimeter.  For 
the four buffers studied, the denaturation of VRC07-523LS is clustered around 70°C.  
The temperature denaturation of VRC07-523LS is irreversible and characterized by an 



















Temp  deg C
Figure 6-1.  The temperature dependence of the heat capacity 
function of VRC07-523LS in the four formulation buffers 
studied, measured by a standard cell microcalorimeter in 
duplicate:  red: buffer 1; blue: buffer 2; green: buffer 3; black: 




exothermic effect associated with 
aggregation and precipitation.  As 
noted before and shown in Figure 6-2 
the calorimetric scans obtained in a 
DSC instrument equipped with 
capillary cells have no visible 
exothermic peak. This phenomenon 
has been known for over thirty years 
(25, 26) and appears to be related to 
the shorter travel path experienced by 
the sample when it aggregates and 
precipitates.  The absence of the 
aggregation/precipitation exotherm in 
the capillary cell DSC reveals the 
presence of the additional 
denaturation peaks of the monoclonal 
antibody, and the possibility of 
analyzing the entire denaturation 
process.  Also, since the exotherm is 
not present a much higher 
reproducibility of the data is achieved.  
Since the denaturation of VRC07-













































































Figure 6-2.  The temperature dependence of 
the heat capacity function of VRC07-523LS in 
the four formulation buffers studied, 
measured by a capillary cell 
microcalorimeter:  red: buffer 1; blue: buffer 
2; green: buffer 3; black: buffer 4.  In this 
figure, the solid lines for each curve represent 
the results of the analysis of the heat capacity 
data to the sum of three irreversible 




capacity data was deconvoluted in terms of a sum of kinetically controlled irreversible 
transitions (57, 58).  For all four buffers, the heat capacity data could be well accounted 
for by three separate transitions.   
The data as well as the calculated heat capacity curves are shown in Figure 6-2.  Each 
transition is characterized by a Tm, a calorimetric enthalpy change (H)  equal to the 
area under each peak and an activation enthalpy (ΔH†) responsible for the temperature 
dependence of the rate of denaturation.  Irreversible transitions are kinetically controlled 
and their Tm is determined by the temperature acceleration of the rate of denaturation 
(57, 58).  The parameters obtained by non-linear least squares analysis of the heat 
capacity function for all four buffers are summarized in Table 6-1.  The Tm of the main 
transition peak is centered around 70oC and increases from buffer 1 through buffer 4.  It 
must be noted that the total increase is only 1.5C and even less between some buffers, 
a difference that can be easily missed in the early stages when the antibody preparation 
has not been optimized.   The same situation is observed for the other transitions as 
Table 6-1 
Deconvolution of Heat Capacity Function of VRC07-523LS * 
Tm’s are in C, the calorimetric enthalpies (H’s) are in kcal/mol and the activation 
energies ∆𝐻†’s are in kcal/mol. 
 







1 68.7 71.9 77.2 462.0 121.4 369.8 173.9 81.93 70.1 
2 69.5 72.4 77.7 459.0 117.4 238.7 169.2 91.9 81.0 
3 69.8 72.5 78.1 445.2 112.2 365.4 169.7 83.6 69.2 
4 70.3 73.1 78.4 461.4 109.7 302.9 167.7 90.8 73.2 
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shown in Table 6-1.  Judging by the Tm values, the rank order of conformational stability 
is buffer 4 > buffer 3 > buffer 2 > buffer 1.   The main transition is characterized by an 
enthalpy change of ~460 kcal/mol and the smaller transitions by enthalpies averaging 
115 and 320 kcal/mol respectively.  Perhaps, more importantly, the activation enthalpy 
of the main transition averages 170 kcal/mol whereas those of the two smaller peaks 
average 87 and 73 kcal/mol respectively.  Since the temperature dependence of the 
rate of denaturation is determined by the activation enthalpy (a smaller positive 
activation enthalpy means a smaller decrease in the rate at lower temperatures, dlnk/dT 
= ΔH†/RT2, see equation 7) the DSC data suggest that at low temperatures the smaller 
transitions might precede the main transition.  If this is the case and the activation heat 
capacities do not alter the trend, these results would suggest that the two smaller 
transitions, which are potentially the CH2 and CH3 domains (61, 62), may be the ones 
that denature and aggregate first at low temperatures. 
With the microcalorimeter equipped with standard “lollipop” cells (Figure 6-1), 
only the main denaturation peak (Tm) is visible and centered at 69.2 ± 0.2 °C for buffer 
1, 69.9 ± 0.1 for buffer 2, 69.9 ± 0.1 for buffer 3 and 70.5 ± 0.2 for buffer 4 which is 
close to the location of the main peaks measured by the capillary DSC.  Since the 
calorimetric signal in the non-capillary DSC instrument is composed of two terms of 
opposite sign, an endotherm due to unfolding and an exotherm due to 
aggregation/precipitation, the exact location of the peak maximum depends on the exact 
separation between the two events which is not necessarily the same under all 
conditions or even separate experiments (63).  Nevertheless, inspection of the data 
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reveals a shoulder around 72.5 – 73.5C probably due to the first minor peak and this 
shoulder immediately precedes the aggregation/precipitation exotherm. 
 
Isothermal Calorimetry.  Isothermal calorimetry (not to be confused with isothermal 
titration calorimetry) measures the rate at which heat is released or absorbed (heat flow) 
by a spontaneous process at constant temperature.   The irreversible denaturation of 
proteins is a kinetically controlled process (58, 64-66).  At low temperatures the rate of 
the reaction is extremely slow and becomes progressively faster as the transition 
temperature is approached.  For 
the initial isothermal calorimetry 
experiments, it is important to 
select a temperature at which the 
reaction occurs with an optimal 
rate for accurate measurements; 
i.e. hours to weeks.  If the 
temperature is too high and the 
reaction occurs within minutes or 
less, the sample will not be able 
to equilibrate and the 
measurement will be impossible.  
On the other hand, if the 
temperature is too low and the 




























Figure 6-3.  Heat flow (dQ/dt) recorded as a 
function of time for VRC07-523LS  in the four 
formulation buffers studied: red: buffer 1; blue: 
buffer 2; green: buffer 3; black: buffer 4. The 
experiment was performed at 60°C at a protein 
concentration of 100 mg/mL in a volume of 1.0 mL.  
The curves in the graph were obtained after 
subtraction of the signal from an ampoule 
containing buffer run in parallel followed by 
normalization by the amount of protein.  In this 





heat production or absorption will be lower than the detection limits of the instrument. A 
good rule of thumb is to perform the first experiments at a temperature 10 degrees 
below Tm, at which the reaction is expected to proceed and complete in several days 
(59).  The temperature for the initial VRC07-523LS isothermal calorimetry experiments 
was set at 60°C.   
Figure 6-3 shows the normalized heat flow for VRC07-523LS at the desired 
formulation concentration of 100mg/mL at 60°C for the four buffers in this study.   All of 
them display an endothermic (positive signal) heat event that decreases monotonically 
until the baseline level is reached.   None of the curves goes below zero, as would have 
been the case if aggregation were slower than denaturation and the two processes 
were separated in time as shown previously (59).  For VRC07-523LS, it appears that 
the two processes (denaturation and aggregation) occur very close to each other and 
that only a composite curve is observed.  Total aggregation of the samples after 
conclusion of the experiments (9 days) was confirmed by visual inspection.  
Examination of the data in Figure 6-3 immediately reveals that buffer 1 exhibits the 
fastest rate of denaturation/aggregation while buffer 4 the slowest one.  Buffers 2 and 3 
exhibit intermediate rates, buffer 2 exhibiting slightly faster denaturation than buffer 3.  
Additionally, the total heat measured by isothermal calorimetry is 540 ± 67 kcal/mol 
which is less than the 890 ± 60 kcal/mol total denaturation enthalpy measured by the 
capillary DSC.  Since the isothermal calorimetry measurement is ten degrees below Tm, 
this difference could be due to the heat capacity of denaturation of the antibody.  
However, the only Cp reported in the literature for the denaturation of a monoclonal 
antibody is by Lazar et al (67) who determined a Cp of 8 kcal/K*mol by chemical 
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denaturation experiments performed at different temperatures.  If we use the Cp value 
determined by Lazar et al, the expected denaturation enthalpy at 60C would be 810 
kcal/mol which is still higher than the 540 kcal/mol measured by isothermal calorimetry.  
Alternatively, if the ΔCp values measured for smaller proteins are extrapolated to the 
molecular weight of an antibody, a ΔCp of 18 kcal/K*mol could be expected (68), in 
which case the enthalpy at 60°C would amount to 710 kcal/mol, also higher than the 
value measured by isothermal calorimetry.  If these values bracket the actual ΔCp, we 
can estimate that the heat of aggregation for VRC07-523LS is on the order of -170 -  -
270 kcal/mol, which is exothermic as expected.     
 
Isothermal Calorimetry Data Analysis.  The heat associated with the unfolding followed 
by aggregation of the protein, relative to that of the native non-aggregated protein is 
proportional to the populations of denatured and aggregated protein.  In general, at any 
degree of unfolding and aggregation of the unfolded state, the heat, QTotal , is equal to: 
 
𝑄𝑇𝑜𝑡𝑎𝑙 = ∆𝐻𝑢𝑣[𝑃𝑢] +  𝑄𝑎𝑔𝑔𝑣[𝑃𝑎𝑔𝑔]                                                    (1) 
 
Where v is the sample volume, [Pu] and [Pagg]  are the concentration of denatured 
(unfolded) and aggregated protein respectively.  ΔHu  and Qagg  are the molar heats of 
unfolding and aggregation respectively.  Equation 1 can be written in terms of the total 
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protein concentration and the fractions of unfolded, Fu, and unfolded aggregated, Fagg, 
protein as follows: 
 
𝑄𝑇𝑜𝑡𝑎𝑙 = ∆𝐻𝑢𝑣[𝑃𝑡]𝐹𝑢 + 𝑄𝑎𝑔𝑔𝑣[𝑃𝑡]𝐹𝑢𝐹𝑎𝑔𝑔                          (2) 
 






= ∆𝐻𝑢𝐹𝑢 + 𝑄𝑎𝑔𝑔𝐹𝑢𝐹𝑎𝑔𝑔                                     (3) 
 
Since denaturation/aggregation are kinetic processes, the fractions of unfolded and 
aggregated protein can be written in terms of the rates of unfolding and aggregation as: 
 
𝑄 = ∆𝐻𝑢(1 − 𝑒
−𝑘𝑢𝑡) + 𝑄𝑎𝑔𝑔(1 − 𝑒
−𝑘𝑢𝑡)(1 − 𝑒−𝑘𝑎𝑔𝑔𝑡)     (4) 
 
Finally,  the quantity directly measured by isothermal calorimetry is the time derivative of 




𝑞 =  𝑘𝑢∆𝐻𝑢𝑒
−𝑘𝑢𝑡 + 𝑘𝑎𝑔𝑔𝑄𝑎𝑔𝑔𝑒
−𝑘𝑎𝑔𝑔𝑡 + 𝑘𝑢𝑄𝑎𝑔𝑔𝑒
−𝑘𝑢𝑡 − (𝑘𝑢 +
            𝑘𝑎𝑔𝑔)𝑄𝑎𝑔𝑔𝑒
−(𝑘𝑢+ 𝑘𝑎𝑔𝑔)𝑡  
                                                                                                                 (5) 
 
Equation 5 accounts for the situation 
depicted in Figure 6-4 (top panel) in which 
the protein denatures or partially denatures 
and then aggregates.  If kagg >> ku the two 
processes will occur at once and 
characterized by a single apparent rate 
constant (Figure 6-4 bottom panel).  In this 
case, the total heat is the sum of the 
unfolding and aggregation heats.  Equation 
5 reduces to: 
 
𝑞 =  𝑘𝑢(∆𝐻𝑢+ 𝑄𝑎𝑔𝑔) 𝑒
−𝑘𝑢𝑡 = 𝑘𝑢𝑄𝑡𝑜𝑡𝑎𝑙𝑒
−𝑘𝑢𝑡 
                                (6) 
Figure 6-4.  Schematic diagram 
showing two different situations for a  
denaturation/aggregation reaction.  In 
the top panel, the rate of denaturation 
or partial denaturation is faster than the 
rate of aggregation resulting in two 
separated and observable reactions.  If 
the rate of aggregation is much faster 
than the rate of denaturation, the two 
reaction collapse into a single transition 





Equation 5 was used to analyze the VRC07-523LS the isothermal calorimetry data.  It 
became immediately apparent that all the data was well accounted by a single 
exponential as described by equation 6.  Figure 6-5 shows the VRC07-523LS 
isothermal calorimetry data obtained at 60°C for the  concentrations of 25, 50 and 
100mg/mL in the four buffers studied in this report as well as the results of the non-
linear least squares fits.  As expected, the signal-to-noise ratio is lower at the lower 
concentrations studied and illustrates the goodness of the data that can be obtained 
with monoclonal antibodies at different concentrations.  In formulation evaluation 
analysis, obtaining data at the formulation concentration (100mg/mL or even higher) is 
critical since most techniques require the use of much lower concentrations that can 
skew the results.  Also, since isothermal calorimetry can be performed at lower 
concentrations, it should be a good screening tool to establish the range of 
concentrations that provide accurate stability answers. 
Figure 6-5.  Non-linear least squares fits of the heat flow versus time data for VRC07-
523LS at three different concentrations in the four formulation buffers studied.  For 
illustration purposes, the heat flow normalized by the total heat, qnorm, has been plotted 
in the figure.  The denaturation/aggregation rates determined by non-linear least squares 




Denaturation/Aggregation Rates at 
60°C.  Figure 6-6 shows the 
denaturation/aggregation rates 
obtained from the analysis of the 
data in Figure 6-5.  It is clear that 
the best buffer according to the 
isothermal calorimetry experiments 
is buffer 4 (k = 0.4 days-1 at 
100mg/mL) and that buffer 1 (k = 1.8 
days-1 at 100mg/mL) is the worst.  
Buffer 2 and 3 occupy a close 
intermediate position but buffer 3 (k = 0.76 days-1 at 100mg/mL) appears to be better as 
it displays lower rates than buffer 2 (k = 0.9 days-1 at 100mg/mL) at all protein 
concentrations.  It is noteworthy that for buffers 2 and 3 and apparently also for buffer 1, 
the rates appear to increase with protein concentration.  Unfolding by itself is a 
monomolecular reaction and therefore independent of concentration.  Aggregation, on 
the other hand, is concentration dependent and its rate is expected to increase at higher 
concentrations, suggesting that in these two buffers the rates of aggregation and 





















Figure 6-6.  The denaturation/aggregation 
rates for VRC07-523LS determined by 
isothermal calorimetry at three different 
concentrations in the four formulation buffers 







dialyzed into the four 
different buffers at a 
final concentration of 
approximately 100 
mg/mL.  The 
antibody was then 
stored for 9 months 
at 5C and 3 months at 25C and 40C and samples were tested at different intervals 
for change in aggregate content (see Materials and Methods). Figure 6-7 shows a 
representative chromatogram obtained after 12 weeks storage at 25°C.   Figure 6-8 
shows the SEC data obtained at 5°C, 25°C and 40°C for several weeks.  In this figure 
the percent monomer population has been plotted as a function of time.  It is evident 
that  at all temperatures the rate of aggregation is faster in buffer 1 while the slowest 
Figure 6-7.  Representative SEC chromatograms of VRC07-
523LS in the four formulation buffers after 12 weeks storage at 
25°C:  red: buffer 1; blue: buffer 2; green: buffer 3; black: buffer 
4. The inset shows zoomed in image of the aggregate peak. 
 
Figure 6-8.  Per cent VRC07-523LS in monomeric form measured by size exclusion 
chromatography (SEC) as a function of time at 5, 25 and 40°C in the four buffers 
studied.  Linear fits to the data are shown as solid lines.  The correlation coefficients 
for buffers 1 through 4 were:  5°C: 0.91, 0.93, 0.89, 0.93; 25°C: 0.99, 0.99, 0.98, 0.99; 




rate is observed in buffer 4.  Buffer 2 and 3 occupy intermediate positions, buffer 3 
being better than buffer 2.  This rank order is the same as the one observed in the 
isothermal calorimetry experiments.  Only at 40°C, the SEC data does not provide a 
robust discrimination between buffers 3 and 4.  Overall, there is a quantitative 
correlation between the rate of monomer dissapearance observed by SEC and the 
denaturation/aggregation rates obtained by isothermal calorimetry as shown in Figure 
6-9.  In this figure, the slopes (percent monomer vs time) calculated from the SEC data 
for the three temperatures studied have been plotted versus the 
denaturation/aggregation rates measured by the isothermal at 60°C.   The correlation is 
excellent and characterized by correlation coefficients of 0.98, 0.91 and 0.86 at 5°C, 
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Figure 6-9.  Correlation between the rate of monomer disappearance obtained 
by SEC at 5, 25, and 40°C, and the denaturation/aggregation rates determined 
by isothermal calorimetry at 60°C and 100mg/mL.  The data points correspond 




Time Dependence of 
Denaturation/Aggregation of 
VRC07-523LS.  The results 
obtained by isothermal calorimetry 
yield the rates of 
denaturation/aggregation which 
allow calculation of the population 
of denatured/aggregated antibody 
as a function of time for the four 
different formulation buffers.  The 
results are shown in Figure 6-10.  
It is clear that the appearance of denatured/aggregated antibody occurs much faster in 
buffer 1 and much more slowly in buffer 4.  In fact, at the incubation temperature of 
60C, in about two days almost all the protein is denatured/aggregated in buffer 1, 
whereas in buffer 4 the same level of denaturation/aggregation only occurs in more than 
ten days.  This observation is not surprising as the essential difference between buffer 1 
and buffer 4 is the addition to the latter of 5% sucrose and 2.5% sorbitol, two excipients 
that stabilize the native state and mitigate aggregation and are widely used in the 
formulation of biologics (15-17, 69, 70). 
Temperature Dependence of Denaturation/Aggregation of VRC07-523LS .  Since the 
combined SEC and the isothermal calorimetry experiments provide rates at four 
different temperatures, it was possible to perform a rigorous thermodynamic analysis in 





























Figure 6-10.  The time dependence for the 
formation of denatured/aggregated VRC07-
523LS antibody at 60°C in the four different 
formulation buffers studied.  The curves were 
calculated with the experimental rates obtained 




VRCO7-523LS.  For this analysis, we chose the data obtained for buffers 1 and 4 which 
represents the two extremes in terms of kinetic rates.  In general the rates can be 
expressed as: 
 






                                     (7) 
 
Where ΔG†, ΔH† and ΔS† are the activations energy, enthalpy and entropy respectively.  
In protein stability it is well known that the enthalpy and entropy are temperature 
dependent due to the existence of a heat capacity difference between the denatured 
and native states (22, 23, 25, 71-75).  Accordingly, the activation enthalpy and entropy 














Figure 6-11 shows 
the results of non-
linear least squares 
fit of the combined 
SEC-isothermal 
calorimetry rate data 
for buffers 1 and 4 to 
equations 7 – 8.  
The data and fits 
have been plotted 
as a function of 
temperature rather 
than the inverse 
temperature in order 
to faciltate visualization.  The resulting parameters at 25°C are summarized in Table 6-2 
and can be used to calculate the rates at any other temperature (equations 7 – 8).  The 
experimental activation energies obtained from the SEC data (ΔG†exp) are very close to 
those obtained from the fits (ΔG†).   Also, at all temperatures the activation energy 
differences between buffers 1 and 4 are small and differ by 0.3 kcal/mol or less at 25°C.  
The data as well as the fits indicate that minor differences in activation energies have 
significant effects in long term stability.  Most importantly is the existence of a change in 
the heat capacity of activation (ΔCp†) on the order of 1.3 kcal/K*mol.  The existence of a 
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Figure 6-11.  Temperature dependence of the long term 
stability of VRC07-523LS (k vs Temp) obtained by combining 
SEC data measured at 5, 25 and 40°C and isothermal 
calorimetry data obtained at 60°C.  The solid lines are the 
results of the non-linear least squares fit of the data using 
equations 7 – 8.  The inset shows the Arrhenius plot (lnk vs 1/T) 




at low temperatures (see inset in Figure 10).   This non-linearity in Arrhenius plots has 
been observed before (see for example (76-78)) and is critical for the prediction of long 
term stability at low temperatures from data obtained at high temperature.  In fact, 
neglecting the non-linearity of the Arrhenius plot grossly exaggerates the expected long 
term stability of a monoclonal antibody as observed before (77).  For example, at 5C 
the monomer is expected to decrease to 50% in 20 - 30 years according to the SEC 
data and the calculated rate considering ΔCp† (Figure 6-10).   
Neglecting the ΔCp† and performing a linear Arrhenius extrapolation of the rate constant 
from high temperature would predict a monomer decrease to 50% in hundreds of years 
as also observed by Drenski et al (77). 
It is tempting to compare the activation energies obtained from the isothermal 
calorimetry kinetic data with the activation energies for the DSC transitions.  If we 
extrapolate the activation energies to 70C, we obtain values on the order of  80 
kcal/mol which are about half the value for the first main transition but closer to the 
values obtained for the second and third transitions.  If this were the case, the main 
culprits for aggregation at low temperatures will be those domains with the smaller 
Table 6-2 












Buffer 1 3.2 3.68 22.4 62.8 1.5 
Buffer 4 3.5 3.93 21.7 59.6 1.2 
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activation enthalpies, since their rate constants are not expected to decrease as fast as 
those with the highest activation enthalpies.  In the literature and depending on the 
monoclonal antibody, the minor peaks have been observed either below or above the 
main transition and are often associated with the denaturation of the CH2 and CH3 
domains (61, 62).   
 
Conclusions 
The aggregation profiles of monoclonal antibodies measured at 5, 25 and 40°C by size 
exclusion chromatography have become a standard piece of information in the 
evaluation of monoclonal antibody developability and formulation optimization.  
However, SEC experiments might take months before providing reliable results, 
especially at low incubation temperatures.  The availability of techniques that might 
provide a quick and accurate ranking of different antibodies and/or formulations would 
greatly benefit the development of protein drugs.  Here, we presented the use of 
isothermal calorimetry as a potential tool to evaluate the expected long term stability of 
monoclonal antibodies in a few days.  Since isothermal calorimetry measures the kinetic 
rates of denaturation/aggregation of proteins below their transition temperature, it may 
play a valuable role in antibody selection and formulation optimization.  Here we have 
shown that the kinetic rates of denaturation/aggregation obtained by isothermal 
calorimetry closely correlates with the SEC data.  Also, a kinetic/thermodynamic 
analysis of the DSC data in conjunction with isothermal calorimetry data provides similar 
rankings for the formulation buffers and clues for the identification of the most likely 
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Chapter 7. Isothermal calorimetry of a monoclonal antibody using a 
conventional differential scanning calorimeter. 
 
This chapter was published in Analytical Biochemistry (Clarkson et. al. 2018). 
Abstract 
It has been previously shown that isothermal calorimetry is able to provide critical 
information regarding the kinetics of denaturation/aggregation of monoclonal antibodies 
at temperatures below Tm or the onset temperature.  Those measurements, however, 
required sophisticated specialized instrumentation.  In this communication, we 
demonstrate that similar measurements can be performed using widely available 
conventional differential scanning calorimeters (DSC) when operated in isothermal scan 
mode. The denaturation/aggregation kinetics of the anti-HIV monoclonal antibody 
VRC07-523LS was previously measured by isothermal calorimetry at ten degrees below 
Tm.  It was observed that the rates measured by isothermal calorimetry correlated 
quantitatively with those measured by size exclusion chromatography, thus suggesting 
that isothermal calorimetry can become a valuable tool for a fast prediction of the best 
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formulations.  In this paper, similar isothermal calorimetry measurements are performed 
with the same antibody using a standard DSC instrument. It is shown that a readily 
available instrument can also provide similar kinetic information. 
Introduction 
Formulating a monoclonal antibody at 100mg/mL or even higher concentrations 
gives rise to different challenges, including maintaining the structural stability of the 
antibody and minimizing any tendency to aggregate over long periods of time (13, 79).   
An important criterion is the long term stability of the antibody.  Unfortunately, 
conventional methods to rapidly predict long term stability are not always reliable.  
Often, results obtained from accelerated conditions do not correlate with aggregation 
pattern observed by size exclusion chromatography (SEC) obtained after long 
incubation times (80, 81). 
Previously, we utilized isothermal calorimetry as a novel technique to measure 
the kinetics of denaturation/aggregation of a monoclonal antibody (VRC07-523LS), and 
compare the results with those obtained by size exclusion chromatography (SEC) (82).  
Isothermal calorimetry is able to measure the rate of heat production or absorption 
associated with the denaturation and aggregation of the antibody at a given temperature 
over days or weeks.  However, in that paper we employed a sophisticated instrument 
(TAM IV, TA Instruments, New Castle, DE, USA) with the capability of measuring up to 
48 samples simultaneously.   In this paper, the kinetics of denaturation/aggregation of 
the monoclonal antibody VRC07-523LS was measured by isothermal calorimetry using 
a widely available capillary DSC instrument operating in the isothermal scan mode.  It is 
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shown, that for measuring single samples this instrument provides a readily accessible 
alternative to more sophisticated instruments. 
Materials and Methods 
Proteins and Reagents:  VRC07-523LS was obtained from the NIH Vaccine Research 
Center (VRC) in Gaithersburg, MD as described earlier (82).  Two different formulation 
buffers were chosen for these studies: buffer 1 (50 mM histidine, 100 mM NaCl, pH 6.8) 
and buffer 4 (50 mM histidine, 50 mM NaCl, 5% w/v sucrose, 2.5% w/v sorbitol, pH 6.8).   
Chemicals for buffer preparation were purchased from multiple vendors: L-Histidine 
(98%, CAS 71-00-1) from Acros Organics (New Jersey, USA), NaCl (Certified 
ACS/Crystalline, CAS 7647-14-5) from Fisher Scientific (Fair Lawn, NJ, USA), and 
sucrose (minimum 99.5%, CAS 57-50-1) and D-sorbitol (minimum 98%, CAS 50-70-4) 
from Sigma-Aldrich (St. Louis, MO, USA). 
Differential Scanning Calorimetry:  Isothermal calorimetry experiments were performed 
using a capillary cell VP-DSC microcalorimeter from MicroCal/Malvern Instruments 
(Northampton, MA, USA). The total volume of the calorimeter cell is 0.5mL.  
Experiments were performed as described in the Results and Discussion section.  Due 
to the high protein concentrations used in long term stability studies, the contents of the 
sample cell at the end of each experiment were a solid paste of precipitated protein.  
The cell was cleaned by successive cycles of removing any excess liquid, adding 
enough 70% nitric acid to fill the cell, and heating the instrument to 80°C until all 
precipitated protein was dissolved as judged by the clarity of the liquid removed from 
the cell after each heating cycle.  Data collection and processing of raw data were 
performed using the software provided with the instrument.  Data analysis was 
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performed using equations described previously (82, 83) and implemented in the 
DataFit software package (Oakdale Engineering, Oakdale, PA, USA). 
Results and Discussion 
Isothermal Calorimetry Using Conventional DSC.  Isothermal calorimetry experiments 
were performed using the isothermal scan mode which is provided in the instrument 
software.  The experiments reported here were performed by using the “constant 
temperature” setting and no instrument feedback.  In our experiments, the “constant 
temperature” setting option was selected instead of the alternative “low noise” option, as 
the instrument did not maintain a precisely constant temperature using the low noise 
option.  Using the constant temperature option, allowed us to perform experiments at 
closely spaced temperatures (e.g. 1C).  It must be noted that at temperatures close to 
the onset transition temperature at which most isothermal calorimetry experiments are 
performed (60 – 62C for VRC07), the denaturation/aggregation rates change 
significantly with temperature and that a precise temperature control must be 
maintained.  Changing the feedback to medium did not have a significant effect 
probably due to the fact that these denaturation/aggregation processes are very slow 
(hours to days).   
Protein solutions of ~50 mg/mL were dialyzed overnight against the desired 
buffer, diluted to the experimental concentration of ~50 mg/mL and thoroughly 
degassed.  Lower protein concentrations were tried but the instrument was not able to 
provide a significant and reproducible signal below 50 mg/mL for this antibody.  Since 
monoclonal antibody formulations usually require 100mg/mL or more, this requirement 
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is not of a particular concern and allows measurements at the formulation 
concentration.   
Experiments were started by loading buffer into the reference and sample cells.  
The instrument was heated to the experimental temperature (e.g. 60C) and held at that 
temperature for 5 minutes.  This step is the equivalent to a buffer-buffer scan in a 
standard DSC experiment.  The instrument was then cooled to 20C and the buffer in 
the sample cell was replaced with protein.  Next, the instrument was quickly (~30 
minutes) heated to the experimental temperature (e.g. 60C).  Once the experimental 
temperature is reached, it is held constant and the differential power (DP) between the 
sample and reference cells is recorded as a function of time.   Experiments were run 
until the differential power stabilized to a constant value.  The average signal for the 
final ~6 hours of the experiment after a constant signal was achieved was considered a 
baseline and subtracted from the rest of the data.  After baseline subtraction, the 
differential signal was normalized per mole of protein and expressed as kcal/day/mol.  
Denaturation/Aggregation of VRC07-523LS at 61C.  The denaturation/aggregation 
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kinetics of VRC07-523LS was 
measured in buffer 1 and 4 at 
61C, which is about nine 
degrees below Tm (82).  The 
experiments were performed in 
the capillary VP-DSC as 
described above.  Figure 7-1 
shows the results of the 
experiments (normalized heat 
flow versus time).  It is clear that 
the experiments are able to 
immediately identify the best 
formulation.  The rate of denaturation/aggregation for buffer 1 at 61C is 3.07 ± 0.014 
days-1 (k-1 = 0.32 days) whereas the rate for buffer 4 is 0.715 ± 0.016 days-1 (k-1 = 1.4 
days).  For both buffers, the area under the curve which corresponds to the total heat of 
denaturation/aggregation was the same, 610 kcal/mol.  Since the reaction in buffer 1 
occurs much faster, the amplitude of the signal is much larger.  For buffer 4, the same 
amount of heat is spread over a longer time and therefore the amplitude is smaller.  The 
rates as well as the heats of denaturation/aggregation are similar to those obtained with 
the TAM IV (82).  As expected, the rates at 61C are somewhat faster than those 
measured at 60C (k = 0.51 days-1 and k = 1.9 days-1 for buffer 4 and 1 respectively). 
For the experiments presented in this work, the signal amplitude was undistinguishable 






























Figure 7-1.  Heat flow (dQ/dt) (experimental data 
and fit) recorded as a function of time for VRC07-
523LS at 61C in buffer 1 (green) and buffer 4 (red).  
The experiments were performed at a protein 
concentration of 50 mg/mL in a volume of 0.518mL.  
The curves in the graph were obtained after 
subtraction of the final baseline followed by 
normalization by the amount of protein.  A positive 




amplitude can be improved 
either by increasing the 
antibody concentration or by 
increasing the temperature.  
For VRC07- 523LS in buffer 4 
a reliable signal could not be 
obtained at temperatures 
lower than 61C using a 50 
mg/mL protein concentration.  
The strong effect of 
temperature is illustrated in 
Figure 7-2 for VRC07- 523LS in buffer 1.  At 60C the rate of denaturation aggregation 
is 1.26 days-1 (k-1 = 0.79 days) compared to the value of 3.07 days-1 (k-1 = 0.32 days) 
measured at 61C.  
Conclusion 
Isothermal calorimetry provides an orthogonal, fast alternative to conventional 
methods for predicting long term stability of biologics.  Since sophisticated isothermal 
calorimeters are not available in most biophysical laboratories, a readily available 
alternative is the use of conventional DSC instruments in the isothermal scan mode.  
This approach can be used to evaluate the validity of isothermal calorimetry data in the 






















Figure 7-2.  Heat flow (dQ/dt) (experimental data and 
fit) recorded as a function of time for VRC07-523LS at 
60C (blue) and 61C (green) in buffer 1.  The 
experiments were performed at a protein 




Acknowledgments:  This work was supported by a grant from the National Science 
Foundation MCB-1157506 (EF).  We also thank Dr. Arne Schon for many helpful 
discussions. 
 
Chapter 8. Conclusions 
 
 It is important to note that the intrinsic conformational stability of proteins 
in solution is perhaps the most important factor in determining their aggregation 
propensity, but there are other factors which can lead to protein aggregation or 
degradation before patient administration.  During post-production handling of protein 
during shipping or storage, or during administration, numerous events may stress the 
protein, only some of which can be mitigated by increased conformational stability 
through the addition of excipients.  Most of these stresses are caused by unintentional 
mishandling on the part of the patient or in some cases the medical staff administering 
the drug, or can even be an unavoidable part of routine handling during production and 
transport.  While patient self-administration is a highly desirable route for patient 
compliance and ease of treatment, it also necessitates formulations that can protect 
against these stresses to an even higher degree than normal.  The different factors that 
can effect drug stability during the period of time between its production and patient 
administration can generally be divided into three categories: mechanical stress 
(including associated contact with interfaces), temperature extremes, and light exposure 
(84).  The effects of temperature extremes and freeze-thaw cycles are usually tested for 
and addressed during formulation design and countered by the addition of stabilizing 
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excipients as discussed previously (84).  Light exposure often occurs during the 
transport of IV bags or while warming up certain drugs for injection and can cause 
photodegradation of proteins and aggregation (84).  This exposure to harmful 
wavelengths of light is combated by secondary packaging to block light exposure, 
although this only guarantees protection from light during transport and storage, but not 
once the drug is in the hands of patients or hospital staff.  Mechanical stress can occur 
accidentally or through routine handling from things like dropping of protein vials or 
aspiration of formulations in syringes and combined with contact with various interfaces 
(liquid-air, liquid-solid, etc.) during mixing or administration can cause conformational 
change and aggregation of the protein (84).  Various nonionic surfactants, like 
polysorbates, are generally added to formulations to prevent adsorption or other 
interactions with surfaces by minimizing the interaction between protein and any 
interfaces (84).  In this way, nonionic surfactants do not increase the stability of the 
protein itself, but rather prevent undesirable interactions with interfaces in order to 
decrease protein aggregation and increase long-term stability during transport, storage 
and administration.  And while this is clearly necessary, especially with drugs that have 
been shown to have adsorption problems or a particular sensitivity to agitation, 
measuring the effect of these excipients is not always straightforward.  Traditional 
techniques that measure protein stability like DSC, ICD, or even isothermal calorimetry, 
reliably capture the effect of stabilizing or solubilizing excipients, but don’t capture the 
effect of limiting undesirable interactions with interfaces very well in a timely way.  
Clearly a traditional long-term stability study using SEC at different time points could 
conceivably capture the effect of surfactants on aggregation during long-term storage, 
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and stirring or agitation could be added to the experimental design as well.  But a better 
understanding of the effects of real-world handling of drug formulations is clearly 
necessary in order to improve formulation design.  Both the extent to which the stresses 
mentioned above impact protein aggregation and degradation, as well as how much the 
efficacy and safety of the drugs are effected, are crucial parts of that understanding.   
Biologics are a crucial part of effective treatment of patient symptoms and 
disease and are rapidly becoming a large focus of the pharmaceutical industry.  While 
more traditional small molecule drugs are very cheap and easy to make, biologics are 
generally significantly more potent and specific.  But biologics are extremely 
complicated to manufacture, characterize, and store, as they are large complex 
molecules that are very sensitive to environmental and storage conditions.  They are 
prone to degradation or aggregation, which not only decreases drug potency, but can 
also cause painful drug administration or severe immune responses in patients.   
I have briefly detailed the most commonly used techniques to measure 
aggregation in drug formulations in order to clarify their utility and short comings in the 
formulation development process.  In short, these techniques do a fair job of 
characterizing the stability of biologics in formulation, but provide little predictive power, 
leading any investigation into the effect of storage conditions on drug stability to 
necessitate long incubation times.  To address this problem, I have developed 
isothermal calorimetry for use with high concentration biologic formulations.  Using this 
technique, the rates of unfolding and aggregation can be measured for proteins under 
formulation conditions at temperatures well below Tm and compared between conditions 
to select the best formulation.  In some situations where very sensitive measurements 
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are called for, such as proteins that are very stable in formulation and therefore only 
minimally aggregate, expensive specialized instrumentation may be required instead of 
a more readily available conventional DSC run in isothermal mode.  Also, while data 
can often be fit by a simple single exponential decay (as presented in this work) to 
extract unfolding or aggregation rate constants, more complicated aggregation 
pathways can lead to isothermal calorimetry data that is difficult to fit in order to extract 
useful information, necessitating the use of other techniques to assist in understanding 
the experimental data.  Finally, isothermal calorimetry is a bulk measurement technique, 
so the interpretation of data for formulations with multiple mAbs in them may be 
complicated to untangle.  But given these minor constraints, isothermal calorimetry is an 
exceedingly useful technique for assessing protein stability in formulation.  Unlike other 
techniques which either hold no predictive power by design (e.g. SEC), or measure 
quantities that may correlate poorly with long-term stability (e.g. ICD), isothermal 
calorimetry measures unfolding and aggregation rates which correlate closely with 
results from long-term stability studies done with SEC.  Furthermore, isothermal 
calorimetry experiments can be conducted with buffer conditions exactly mimicking 
those in formulation rather than being limited to only low protein concentrations or 
certain buffers.  In fact, the signal to noise ratio of isothermal calorimetry data improves 
with increased protein concentration, making it ideal for use with high concentration 
formulations.  
Protein stability and aggregation is a complicated balancing act of interactions 
between the protein and solvent, the protein and other proteins, numerous types of 
forces like the hydrophobic effect and ionic bonds, the actual physical conditions 
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present, and numerous others.  This confluence of factors makes a complete and 
thorough understanding of these processes complicated, and any new pieces of 
information can unlock a further understanding.  The ability to measure the rate of 
unfolding and/or aggregation under the exact physical and chemical conditions present 
in formulation is crucial to a complete understanding of proteins in formulation, 
particularly because its interpretation is so straightforward.  Comparing the aggregation 
rate to other well established measurements like ΔG or more difficult to interpret values 
can also assist in a deeper understanding of the way different parameters effect the 
aggregation behavior of proteins.   
Techniques like AUC and chemical denaturation have been irreplaceable in 
forming our current knowledge of protein aggregation, and continue to be an important 
part of formulation development and scientific research, particularly due to the 
complicated aggregation pathways of many large molecules involving partially 
denatured states.  But in terms of predicting the shelf life of biologics and better 
understanding their long-term aggregation kinetics, isothermal calorimetry fills an empty 
niche.  It can obtain useful quantitative information on proteins at the high 
concentrations used in formulations (~100 mg/mL) and with relatively mild denaturing 
conditions, and can provide useful information with less necessary extrapolation than 
techniques which use lower protein concentrations or high temperatures or denaturant 
concentrations.  Isothermal calorimetry does a very good job at predicting the results 
obtained using much more time consuming techniques like SEC, so the adoption of 
isothermal calorimetry as part of formulation development could significantly decrease 
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the required time for shelf-life prediction, thereby decreasing the time required to get 
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 Teaching assistant for undergraduate lab classes in biochemistry and cell 
biology. Responsibilities included setting up and running lab classes and grading 
weekly assignments and exams. 
 Lead teaching assistant for graduate course in biophysical chemistry. 
Responsibilities included running computational labs related to lecture material, 
grading weekly assignments and labs, running exam review sessions, and 
tutoring students.  
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